Patent Application
20160176816
The present invention relates to novel muscarinic M3 receptor antagonists, and more particularly, to novel biphenyl derivatives having muscarinic M3 receptor antagonist activity, or isomers thereof, pharmaceutically acceptable salts thereof, or hydrates thereof, methods for preparing the same, and a pharmaceutical composition containing the same as an active ingredient.
Muscarinic receptors are found in all parts of the human body, including the brain and salivary glands. Such receptors are members of G-protein coupled receptors, and are further divided into five subtypes (M1 to M5). Among these subtypes, M1, M2 and M3 receptors are extensively found in tissues of animal and human, and their pharmacological properties have been elucidated. Muscarinic M1 receptor is expressed mainly in cerebral cortex, and is involved in the regulation of higher cognitive functions. The M2 receptor is found mainly in heart and bladder smooth muscles, and is involved in regulation of heart rate. It is known that the M3 receptor is extensively expressed in many peripheral tissues and is involved in stimulation of the gastrointestinal tract and the urinary tract, and salivation. The M4 and M5 receptors are found in the brain, and the M4 receptor is mainly involved in movement, but the role of the M5 receptor remains obscure.
Generally, it was found that muscarinic receptor antagonists are useful for the treatment of various diseases, for example, chronic obstructive pulmonary disease, asthma, irritable bowel syndrome, urinary incontinence, rhinitis, spasmodic colitis, chronic cystitis, Alzheimer's disease, senile dementia, glaucoma, schizophrenia, gastroesophageal reflux disease, cardiac arrhythmia, and hyper-salivation syndromes (Invest. Drugs, 1997, 6 (10), 1395-1411, Drugs Future, 1997, 22 (2) 135-137, Drugs Future, 1996, 21 (11), 1105-1108, Drugs Future, 1997, 22 (7), 733-737).
Meanwhile, it is known that, among the muscarinic receptors, the M2 and M3 receptors are predominant in human bladder and play a role in the regulation of bladder contraction. The M2 receptor is present in the bladder in an amount that is at least three times larger than the M3 receptor, and it plays a role in inhibiting bladder relaxation by beta-receptor rather than being involved directly in bladder contraction. Thus, the M3 receptor appears to play the most important role in bladder contraction. Therefore, selective antagonists against the M3 receptor exhibit excellent inhibitory effects against muscarinic bladder contraction, but inhibit salivary secretion to cause dry mouth.
Accordingly, the present inventors have prepared novel derivatives that can exhibit functional activity by their selective binding to the muscarinic M3 receptor and have minimized side effects, thereby completing the present invention.
It is an object of the present invention to provide novel biphenyl derivatives or pharmaceutically acceptable salts thereof.
Another object of the present invention is to provide methods for preparing novel biphenyl derivatives or pharmaceutically acceptable salts thereof.
Still another object of the present invention is to provide a muscarinic M3 receptor antagonist containing novel biphenyl derivatives, pharmaceutically acceptable salts thereof, or hydrates thereof as an active ingredient.
The present invention provides novel biphenyl derivatives or pharmaceutically acceptable salts thereof.
The present invention also provides methods for preparing novel biphenyl derivatives or pharmaceutically acceptable salts thereof.
The present invention also provides muscarinic M3 receptor antagonists containing novel biphenyl derivatives, pharmaceutically acceptable salts thereof, or hydrates thereof as an active ingredient.
As used herein, the term “alkyl” means a straight or branched hydrocarbon radical. For example, C1-C6 alkyl is an aliphatic hydrocarbon having 1 to 6 carbon atoms, and is intended to include all methyl, ethyl, propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, neopentyl, isopentyl and the like.
As used herein, the term “alkoxy” means a radical wherein the hydrogen atom of a hydroxyl group is substituted with alkyl. For example, C1-C6 alkoxy is intended to include all methoxy, ethoxy, propoxy, n-butoxy, n-pentyloxy, isopropoxy, sec-butoxy, tert-butoxy, neopentyloxy, isopentyloxy and the like.
Novel Biphenyl Derivatives
The present invention provides novel biphenyl derivatives represented by the following Formula 1, or pharmaceutically acceptable salts thereof:
wherein:
R1 is hydrogen, halogen, hydroxy, substituted or unsubstituted C1-C6 alkyl, or C1-C6 alkoxy;
R2, R3 and R4 are each independently hydrogen, halogen, substituted or unsubstituted amino, nitro, cyano, hydroxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, or —C(O)R6;
R5 is hydrogen or C1-C6 alkyl;
n is 0 or 1; and
R6 is hydrogen or amino.
In a preferred embodiment of the present invention, R1 in Formula 1 may be hydrogen or halogen; R2, R3 and R4 may each independently be hydrogen, halogen, or C1-C6 alkyl; and R5 may be C1-C6 alkyl.
In another preferred embodiment of the present invention, R1 in Formula 1 may be hydrogen; R2, R3 and R4 may each independently be hydrogen or halogen; R5 may be C1-C6 alkyl; and n may be 0 or 1.
In the present invention, the pharmaceutically acceptable salts are preferably acid addition salts formed with pharmaceutically acceptable free acids. Free acids that may be used in the present invention include organic acids and inorganic acids. The inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, etc, and the organic acids include citric acid, acetic acid, lactic acid, maleic acid, coumaric acid, gluconic acid, methanesulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, trifluoroacetic acid, galacturonic acid, embonic acid, glutamic acid, aspartic acid, etc.
In addition, the compounds of Formula 1 or pharmaceutically acceptable salts thereof can show polymorphism, and can also exist as solvates (e.g., hydrates, etc.). Furthermore, the compounds of the present invention can also exist as individual stereoisomers or mixtures of stereoisomers.
The present invention is also directed to novel biphenyl derivatives selected from the group consisting of the following compounds:
Methods for Preparation of Novel Biphenyl Derivatives
The present invention provides methods for preparing the compounds of formula 1 or pharmaceutically acceptable salts thereof (Preparation Methods 1 to 4).
Preparation Method 1
The method for preparing the compounds of formula 1 or pharmaceutically acceptable salts thereof according to the present invention may comprise a step of reacting a compound of the following formula 2 with a compound of the following formula 3 in the presence of a carbamate synthesis reagent:
wherein R1 to R5 and n are the same as defined in formula 1.
The carbamate synthesis reagent preferably comprises an azide compound. Specifically, the carbamate synthesis reagent that is used in the present invention may be a mixture of diphenylphosphoryl azide (DPPA) and triethylamine, a mixture of propylphosphonic anhydride (T3P), trimethylsilyl azide (TMSN3) and triethylamine, a mixture of sodium azide (NaN3), tetrabutylammonium bromide and zinc(II) triflate, or the like.
In addition, the carbamate synthesis reaction may be performed at a temperature between 100° C. and 120° C. for 4 to 12 hours.
Preparation Method 2
In addition, the method for preparing the compounds of formula 1 or pharmaceutically acceptable salts thereof according to the present invention may comprise the steps of: reacting a compound of the following formula 2 with a compound of the following formula 3a in the presence of a carbamate synthesis reagent to prepare a compound of the following formula 4; removing an amine protecting group from the compound of formula 4 to prepare a compound of the following formula 1a; and introducing an R5 substituent into the compound of formula 1a:
wherein R1 to R4 and n are the same as defined in formula 1, and PG1 is an amine protecting group which may be selected from the group consisting of Boc (tert-butyloxycarbonyl), benzyl, tert-butyl, PMB (4-methoxybenzyl), Fmoc (fluorenylmethyloxycarbonyl), Ts (tosylate), MOM (methoxymethyl), THP (tetrahydropyranyl), TBDMS (tert-butyldimethylsilyl), and TBDPS (tert-butyldimethylsilyl).
The carbamate synthesis reagent and the reaction conditions are the same as described above for preparation method 1.
In addition, palladium-carbon (Pd—C), a strong acid such as trifluoroacetic acid, sulfuric acid, hydrobromic acid or the like; or a base such as piperidine; ammonium cerium (IV) nitrate; tetra-n-butyl ammonium fluoride or the like may be used in the reaction of removing amine protecting group. The reaction may be carried out at room temperature for 3 to 12 hours.
In addition, the reaction of introducing the R5 substituent may be carried out using formaldehyde solution, acetic acid and zinc, or may be carried out using alkyl halide, potassium carbonate, potassium iodide or triethylamine. Water or dimethylformamide may be used as a solvent. The reaction may be performed at room temperature to 120° C. for 5-12 hours.
Meanwhile, the compound of formula 2 can be prepared by a method comprising the steps of: reacting a compound of the following formula 5 in the presence of an acid to prepare a compound of the following formula 6, which has a carboxylic acid protecting group introduced therein; coupling the compound of formula 6 with a compound of the following formula 7 to prepare a compound of the following formula 8; and de-esterifying the compound of formula 8 in the presence of a base:
wherein R1 to R5 and n are the same as defined in formula 1; X is halogen; and PG2 is a protecting group that may be selected from the group consisting of a C1-C4 alkyl group, benzyl, PMB (4-methoxybenzyl), THP (tetrahydropyranyl), TBDMS (tert-butyldimethylsilyl), and TBDPS (tert-butyldimethylsilyl).
In the reaction of introducing the carboxylic acid protecting group, thionyl chloride or sulfuric acid is preferably used as the acid, and ethanol or methanol may be used as a solvent. The reaction may be performed at a temperature between 80° C. and 100° C. for 4 to 24 hours.
In addition, the base that is used in the coupling reaction is preferably selected from among potassium carbonate and sodium carbonate. A catalyst that is used in the coupling reaction may be tetrakistriphenylphosphine palladium or dichlorobistriphenylphosphine palladium, and a solvent that is used in the coupling reaction may be toluene, a mixture of toluene and ethanol, a mixture of ethanol and water, a mixture of acetonitrile and water, or the like. Furthermore, the coupling reaction may be performed at a temperature between 100° C. and 120° C. for 10 minutes to 12 hours.
Furthermore, the base that is used in the de-esterification reaction is preferably selected from among sodium hydroxide and potassium hydroxide, and a solvent that is used in the de-esterification reaction may be ethanol or a mixture of ethanol and water. The de-esterification reaction may be performed at a temperature between 100° C. and 120° C. for 2 to 12 hours.
Preparation Method 3
In addition, the method for preparing the compounds of formula 1 or pharmaceutically acceptable salts thereof according to the present invention may comprise the steps of: reacting a compound of the following formula 5 with a compound of the following formula 3 in the presence of a carbamate synthesis reagent to prepare a compound of the following formula 9; and coupling a compound of the following formula 7 to the compound of formula 9:
wherein R1 to R5 and n are the same as defined in formula 1, and X is halogen.
The carbamate synthesis reagent and the reaction conditions are the same as described above for preparation method 1.
In addition, the coupling reaction reagents and the reaction conditions are the same as described above for preparation method 2.
Preparation Method 4
In addition, the method for preparing the compounds of formula 1 or pharmaceutically acceptable salts thereof according to the present invention may comprise the steps of: reacting a compound of the following formula 5 with a compound of the following formula 3a in the presence of a carbamate synthesis reagent to prepare a compound of the following formula 9a; deprotecting the compound of formula 9a to obtain a compound of the following formula 9b; introducing an R5 substituent into the compound of the formula 9b to prepare a compound of the following formula 9; and coupling a compound of the following formula 7 to the compound of formula 9:
wherein R1 to R5 and n are the same as defined in formula 1; X is halogen; and PG1 is the same as defined in preparation method 2.
The carbamate synthesis reagent and the reaction conditions are as described above for preparation method 1.
In addition, the deprotection reaction, the reaction of introducing the R5 substituent and the coupling reaction are as described above for preparation method 2.
Pharmaceutical Composition Containing Novel Biphenyl Derivatives
The present invention provides a muscarinic M3 receptor antagonist containing the compound of formula 1, an isomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate thereof as an active ingredient.
In the present invention, the muscarinic M3 receptor antagonist may be a composition for the prevention or treatment of a disease selected from the group consisting of chronic obstructive pulmonary disease, asthma, irritable bowel syndrome, urinary incontinence, rhinitis, spasmodic colitis, chronic cystitis, Alzheimer's disease, senile dementia, glaucoma, schizophrenia, gastroesophageal reflux disease, cardiac arrhythmia, and hyper-salivation syndromes.
In the present invention, the muscarinic M3 receptor antagonist may contain, in addition to the compound of formula 1 or a pharmaceutically acceptable salt thereof, one or more active ingredients showing a function equal or similar to the compound of formula 1 or a pharmaceutically acceptable salt thereof.
For administration, the composition of the present invention may further comprise at least one pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier that is used in the composition of the present invention may be physiological saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, or a mixture of one or more thereof. If necessary, other conventional additives such as antioxidants, buffers or bacteriostatic agents may be added to the composition of the present invention. In addition, diluents, dispersants, surfactants, binders and lubricants may further be added to the composition to formulate injectable formulations such as aqueous solutions, suspensions or emulsions, pills, capsules, granules or tablets. Furthermore, the composition of the present invention may preferably be formulated depending on particular diseases or their components, using a suitable method known in the art or the method described in Remington's Pharmaceutical Science, Merck Publishing Company, Easton Pa.
In addition, when the muscarinic M3 receptor antagonist of the present invention is for oral administration, the compound of formula 1 or a pharmaceutically acceptable salt thereof may be contained in an amount of 1-95 wt %, preferably 1-70 wt %, based on the total weight of the M3 receptor antagonist.
The pharmaceutical composition of the present invention may be administered orally or may be administered parenterally in the form of injectable solutions, suppositories, transdermal agents, inhalation agents or intravesical agents.
The present invention also provides a method for treating or alleviating a disease caused by decline of the activity on muscarinic M3 receptor, the method comprising administering a muscarinic M3 receptor antagonist containing the compound of formula 1 or a pharmaceutically acceptable salt as an active ingredient to mammals including humans in need of muscarinic M3 receptor antagonist activity.
The muscarinic M3 receptor antagonist of the present invention may be used alone or in combination with surgery, hormone therapy, drug therapy and a biological response modifier in order to prevent or treat a disease caused by decline of the activity on muscarinic M3 receptor.
Method for Prevention or Treatment of Muscarinic M3 Receptor-Related Diseases
The present invention also provides a method for preventing or treating a muscarinic M3 receptor-related disease, for example, a disease selected from among chronic obstructive pulmonary disease, asthma, irritable bowel syndrome, urinary incontinence, rhinitis, spasmodic colitis, chronic cystitis, Alzheimer's disease, senile dementia, glaucoma, schizophrenia, gastroesophageal reflux disease, cardiac arrhythmia, and hyper-salivation syndromes, the method comprising administering to subjects in need thereof a composition containing, as an active ingredient, the compound of formula 1, or an isomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
The composition that is used in the preventing or treating method of the present invention includes the pharmaceutical composition as described herein.
In addition, the subjects in need of the preventing or treating method of the present invention include mammals, particularly humans.
The biphenyl derivatives according to the present invention have affinity and selectivity for the muscarinic M3 receptor and less toxic. Thus, these biphenyl derivatives can be used as agents for preventing or treating various diseases, particularly urinary system diseases such as enuresis, nervous pollakiuria, neurogenic bladder, unstable bladder, chronic cystitis, cystospasm, urinary incontinence, or frequent urination, respiratory system diseases such as chronic obstructive pulmonary disease, chronic bronchitis, asthma, or rhinitis, and digestive diseases such as irritable bowel syndrome, spastic colitis or diverticulitis, in which the muscarinic M3 receptor is involved.
Particularly, because the biphenyl derivatives of the present invention have high selectivity for the muscarinic M2 receptor and the muscarinic M3 receptor that is present in smooth muscles, gland tissues and the like, these biphenyl derivatives are M3 receptor antagonists having less side effects, and thus are very useful as agents for preventing or treating urinary incontinence, frequent urination, chronic bronchitis, chronic obstructive pulmonary disease, asthma, rhinitis, and the like.
The present disclosure will be described more fully hereinafter with reference to the accompanying synthesis examples, examples and experimental examples. However, the Examples according to the present invention can be modified in various ways, and the scope of the present invention should not be interpreted as being limited to the following Examples. The Examples of the present invention are provided so that those skilled in the art can sufficiently understand the present invention.
Furthermore, agents stated hereinafter were purchased from Aldrich Korea, Acros, Lancaster, TCI unless otherwise specified. 1H NMR used herein was Varian 400 MHz, and Microwave oven used herein was Monowave 300 of Anton Paar company.
2-Bromobenzoic acid (5 g, 24.87 mmol) was dissolved in ethanol (100 mL). Sulfuric acid (5 mL) was added thereto and stirred under reflux for 24 hours. After reaction was terminated, the reactant was cooled to room temperature. The solvent was removed by concentrating the reactant under reduced pressure, and extracted with water and ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (4.9 g, 86%).
Ethyl-2-bromobenzoate (1 g, 4.37 mmol) prepared in Step 1 was dissolved in a mixed solution of toluene (20 mL) and ethanol (4 mL), and then 4-fluorophenyl boronic acid (672 mg, 4.80 mmol), potassium carbonate (1.21 g, 8.73 mmol) and tetrakis triphenylphosphine palladium (504 mg, 0.44 mmol) were added thereto. The reactant was stirred at 100° C. for 6 hours, cooled to room temperature and filtered through celite. The solvent was removed by concentrating the reactant under reduced pressure. The same was extracted with water and ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (948 mg, 89%).
Ethyl 4′-fluoro-[1,1′-biphenyl]-2-carboxylate (948 mg, 3.33 mmol) prepared in Step 2 was dissolved in ethanol (20 mL). 2N-sodium hydroxide solution (5.82 mL, 11.64 mmol) was added thereto and stirred under reflux for 12 hours. The reactant was cooled to room temperature. The solvent was removed by concentrating the reactant under reduced pressure. The same was extracted with 1N-hydrochloric acid and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated to prepare the titled compound (747 mg, 89%).
2-Bromobenzoic acid as a starting material and reacting materials in Table 1 were used to prepare compounds of Synthesis Examples 2-15 in the same manner as Synthesis Example 1.
2-Bromo-4-fluorobenzoic acid (2.37 g, 10.82 mmol) was dissolved in ethanol (100 mL). Thionyl chloride (1.57 mL, 21.64 mmol) was added thereto and stirred under reflux for 24 hours. The reactant was cooled to room temperature after the reaction was terminated. The solvent was removed by concentrating the reactant under reduced pressure. The same was extracted with water and ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (2.29 g, 87%).
Ethyl 2-bromo-4-fluorobenzoate (1.1 g, 4.47 mmol) prepared in Step 1 was dissolved in toluene (20 mL). 3-Chlorophenyl boronic acid (766 mg, 4.90 mmol), potassium carbonate (1.23 g, 8.90 mmol) and tetrakis triphenylphosphine palladium (520 mg, 0.44 mmol) were added thereto. The reactant was stirred at 100° C. for 6 hours and cooled to room temperature. The same was filtered through celite and the solvent was removed by concentrating the reactant under reduced pressure. The same was extracted with water and ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (850 mg, 69%).
Ethyl 3′-chloro-5-fluoro-[1,1′-biphenyl]-2-carboxylate (850 mg, 3.05 mmol) prepared in Step 2 was dissolved in ethanol (20 mL). 2N-sodium hydroxide solution (4.57 mL, 9.15 mmol) was added thereto and stirred under reflux for 12 hours. The reactant was cooled to room temperature. The solvent was removed by concentrating the reactant under reduced pressure and extracted with 1N-hydrochloric acid and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated to prepare the titled compound (650 mg, 85%).
The starting materials and reacting materials in Table 2 were used to prepare compounds of Synthesis Examples 17-26 in the same manner as Synthesis Example 16.
2-Iodobenzoic acid (1 g, 4.03 mmol) was dissolved in toluene (50 mL). Biphenylphosphoryl azide (1.04 mL, 4.84 mmol) and triethylamine (566 μL, 4.03 mmol) were added thereto. The same was stirred at room temperature for 30 minutes, and then stirred under reflux for 1 hour. The reactant was cooled to room temperature. 2-(2-Hydroxyethyl)-1-methylpyrrolidine (651 μL, 4.84 mmol) was added thereto and stirred under reflux for 12 hours. The reactant was cooled to room temperature. The solvent was removed by concentrating the reactant under reduced pressure and the same was extracted with water and ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (1.16 g, 77%).
The starting materials in Table 3 were used instead of 2-iodobenzoic acid to prepare compounds of Synthesis Examples B-E in the same manner as Synthesis Example A.
2-Bromobenzoic acid (4.5 g, 22.4 mmol) was dissolved in toluene (100 mL) and biphenylphosphoryl azide (5.8 mL, 26.9 mmol) and triethylamine (3.15 mL, 22.4 mmol) were added thereto. The same was stirred at room temperature for 30 minutes, and then stirred under reflux for 1 hour. The reactant was cooled to room temperature, (R)-tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate (5.41 g, 26.9 mmol) was added thereto, and stirred under reflux for 12 hours. The reactant was cooled to room temperature. The solvent was removed by concentrating the reactant under reduced pressure. The same was extracted with water and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (8.1 g, 91%).
(R)-tert-butyl-3-((((2-bromophenyl)carbamoyl)oxy)-methyl)-pyrrolidine-1-carboxylate (8.1 g, 20.29 mmol) prepared in Step 1 was dissolved in dichloromethane (100 mL). Trifluoroacetic acid (50 mL) was added thereto and stirred at room temperature for 2 hours. The solvent was removed by concentrating the reactant under reduced pressure, and the same was extracted with 2N-sodium hydroxide solution and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (3.94 g, 65%).
(R)-pyrrolidin-3-ylmethyl(2-bromophenyl)carbamate (3.94 g, 13.13 mmol) prepared in Step 2 was dissolved in water (100 mL). Acetic acid (5 mL), formaldehyde solution (15 mL) and zinc powder (1.5 g) were sequentially added thereto and stirred at room temperature for 12 hours. The reactant was filtered, neutralized with 2N-sodium hydroxide solution and extracted with water and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (3.06 g, 75%).
The starting materials and reacting materials in Table 4 were used to prepare compounds of Synthesis Examples G-L in the same manner as Synthesis Example F.
2-Bromobenzoic acid (2 g, 9.95 mmol) was dissolved in toluene (75 mL), and then biphenylphosphoryl azide (2.57 mL, 11.94 mmol) and triethylamine (1.4 mL, 9.95 mmol) were added thereto. The same was stirred at room temperature for 30 minutes, and then stirred under reflux for 1 hour. The reactant was cooled to room temperature. (S)-(1-methylpyrrolidin-2-yl)methanol (1.42 mL, 11.94 mmol) was added thereto and stirred under reflux for 4 hours. The reactant was cooled to room temperature. The solvent was removed by concentrating the reactant under reduced pressure. The same was extracted with water and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (1.4 g, 45%).
The starting materials and reacting materials in Table 5 were used to prepare compounds of Synthesis Examples N-P in the same manner as Synthesis Example M.
1H NMR (CDCl3): δ 8.10- 7.99(m, 1H), 7.38- 7.26(m, 3H), 7.20- 7.06(m, 4H), 6.52- 6.41(bs, 1H), 4.21- 4.08(m, 2H), 3.12- 2.99(m, 1H), 2.29(m, 3H), 2.20-1.87(m, 4H), 1.83-1.61(m, 2H), 1.61-1.40(m, 2H)
1H NMR (CDCl3): δ 8.11- 7.96(m, 1H), 7.45- 7.32(m, 1H), 7.21- 7.07(m, 2H), 6.98- 6.79(m, 3H), 6.55- 6.39(bs, 1H), 4.27- 4.10(m, 2H), 3.14- 2.99(m, 1H), 2.30(s, 3H), 2.21-1.85(m, 4H), 1.85-1.41(m, 4H)
1H NMR (CDCl3): δ 8.00- 7.88(m, 1H), 7.43- 7.30(m, 1H), 7.29- 7.08(m, 2H), 7.05- 6.91(m, 2H), 6.69- 6.52(bs, 1H), 4.25- 4.06(m, 2H), 3.25- 3.08(m, 1H), 2.47- 2.17(m, 5H), 2.14- 1.91(m, 2H), 1.90- 1.45(m, 4H)
1H NMR (CDCl3): δ 8.13- 7.96(m, 1H), 7.50- 7.28(m, 2H), 7.22- 7.00(m, 5H), 6.60- 6.45(bs, 1H), 4.25- 4.07(m, 2H), 3.13- 2.99(m, 1H), 2.31(s, 3H), 2.22-1.41(m, 8H)
1H NMR (CDCl3): δ 8.13- 7.99(m, 1H), 7.35- 7.22(m, 4H), 7.20- 7.14(m, 1H), 7.12- 7.06(m, 1H), 7.03- 6.95(m, 2H), 6.63- 6.56(bs, 1H), 4.23- 4.10(m, 2H), 3.85(s, 3H), 3.10-3.01(m, 1H), 2.28(s, 3H), 2.17- 1.88(m, 4H), 1.84- 1.62(m, 2H), 1.62- 1.41(m, 2H)
1H NMR (CDCl3): δ 8.11(s, 1H), 7.45 (t, 1H), 7.38 (d, 1H), 7.34(dd, 2H), 7.21(dd, 2H), 7.12(t, 1H), 6.99(t, 1H), 6.64(s, 1H), 4.18-4.14(m, 2H), 3.09-3.01(m, 1H), 2.40(s, 3H), 2.34(m, 3H), 2.12-2.06(m, 2H), 1.91-1.82(m, 1H), 1.78-1.66(m, 2H), 1.60-1.56(m, 1H)
1H NMR (CDCl3): δ 8.11- 7.94(m, 1H), 7.55- 6.97(m, 7H), 6.55- 6.35(bs, 1H), 4.25- 3.98(m, 2H), 3.14- 2.94(m, 1H), 2.29(s, 3H), 2.20-1.84(m, 4H), 1.81-1.37(m, 4H)
1H NMR (CDCl3): δ 8.06(s, 1H), 7.41- 7.35(m, 4H), 7.26- 7.22(m, 1H), 7.19- 7.16(m, 1H), 7.14- 7.10(m, 1H), 6.47(s, 1H), 4.22-4.15(m, 2H), 3.07-3.02(m, 1H), 2.29(s, 3H), 2.16- 2.06(m, 2H), 2.03- 1.91(m, 2H), 1.78- 1.62(m, 2H), 1.60- 1.47(m, 2H)
1H NMR (CDCl3): δ 8.01(s, 1H), 7.39- 7.35(m, 2H), 7.22- 7.20(m, 2H), 7.17- 7.11(m, 2H), 6.42(s, 1H), 4.22-4.13(m, 2H), 3.10-3.01(s, 1H), 2.30(s, 3H), 2.08- 2.04(m, 2H), 2.03- 1.90(m, 2H), 1.78- 1.60(m, 2H), 1.58- 1.42(m, 2H)
1H NMR (CDCl3): δ 8.03(s, 1H), 7.39- 7.34(m, 3H), 7.31- 7.291(m, 2H), 7.19- 7.11(m, 2H), 6.44(s, 1H), 4.24-4.15(m, 2H), 3.04-3.00(m, 1H), 2.27(s, 3H), 2.04- 2.01(m, 2H), 2.00- 1.88(m, 2H), 1.80- 1.63(m, 2H), 1.59- 1.44(m, 2H)
1H NMR (CDCl3): δ 8.27- 8.24(m, 1H), 7.55- 7.52(m, 1H), 7.41- 7.37(m, 1H), 7.22- 7.00(m, 3H), 7.01- 6.97(m, 1H), 4.14- 4.05(m, 2H), 3.37- 3.35(m, 1H), 2.50(s, 3H), 2.10-2.04(m, 2H), 1.93-1.88(m, 2H), 1.81-1.77(m, 2H), 1.66-1.62(m, 2H)
1H NMR (CDCl3): δ 8.10- 7.92(m, 1H), 7.73- 7.46(m, 3H), 7.44- 7.31(m, 1H), 7.31- 7.05(m, 2H), 6.55- 6.34(bs, 1H), 4.26- 4.02(m, 2H), 3.20- 3.00(m, 1H), 2.31(s, 3H), 2.25-1.88(m, 4H) 1.86-1.40(m, 4H)
1H NMR (CDCl3): δ 8.04(s, 1H), 7.72(d, 2H, J = 8.0), 7.48(d, 2H, J = 8.4), 7.41- 7.36(m, 1H), 7.20- 7.13(m, 2H), 6.41(s, 1H), 4.18-4.14(m, 2H), 3.06-3.01(s, 1H), 2.27(s, 3H), 2.18- 2.04(m, 2H), 2.02- 1.87(m, 2H), 1.77- 1.68(m, 2H), 1.57- 1.43(m, 2H)
1H NMR (CDCl3): δ 8.11- 7.99(m, 1H), 7.39- 7.30(m, 1H), 7.30- 7.14(m, 2H), 7.14- 7.07(m, 1H), 7.06- 6.95(m, 2H), 6.64- 6.54(bs, 1H), 4.26- 4.08(m, 2H), 3.30- 3.09(m, 1H), 2.36(s, 3H), 2.32(s, 3H), 2.30-2.14(m, 2H), 2.13- 1.92(m, 2H), 1.92- 1.46(m, 4H)
1H NMR (CDCl3): δ 8.10(s, 1H), 7.38- 7.33(m, 2H), 7.26- 7.17(m, 3H), 7.15- 7.09(m, 1H), 6.66(s, 1H), 4.19-4.16(m, 2H), 3.21-3.01(s, 1H), 2.41(s, 3H), 2.28(s, 3H), 2.23-2.12(m, 2H), 2.10-1.91(m, 2H), 1.83-1.63(m, 2H), 1.60-1.43(m, 2H)
1H NMR (CDCl3): δ 8.10(s, 1H), 7.37- 7.31(m, 2H), 7.23- 7.18(m, 2H), 7.11- 7.08(m, 1H), 7.00- 6.86(m, 2H), 6.70(s, 1H), 4.17-4.01(m, 4H), 3.18-3.15(m, 1H), 2.36(s, 3H), 2.23- 2.16(m, 2H), 2.08- 1.91(m, 2H), 1.81- 1.71(m, 2H), 1.63- 1.41(m, 2H), 1.40- 1.38(m, 3H)
1H NMR (CDCl3): δ 7.94(s, 1H), 7.41- 7.36(m, 2H), 7.32(s, 1H), 7.22-7.20(m, 1H), 7.07-7.02(m, 1H), 6.92-6.89(m, 1H), 6.38(s, 1H), 4.17- 4.13(m, 2H), 3.04- 3.00(m, 1H), 2.27(s, 3H), 2.15-2.03(m, 2H), 2.00-1.87(m, 2H), 1.80-1.64(m, 2H), 1.56-1.40(m, 2H)
1H NMR (CDCl3): δ 7.86(s, 1H), 7.44- 7.39(m, 1H), 7.26- 7.22(m, 1H), 7.17- 7.08(m, 1H), 7.06- 7.02(m, 1H), 7.01- 6.91(m, 2H), 6.75(s, 1H), 4.15-4.06(m, 2H), 3.30-3.27(m, 1H), 2.47(s, 3H), 2.10- 1.93(m, 2H), 1.87- 1.73(m, 2H), 1.70- 1.54(m, 2H)
1H NMR (CDCl3): δ 7.97(s, 1H), 7.32- 7.26(m, 1H), 7.24- 7.21(m, 1H), 7.19- 7.13(m, 2H), 7.07- 7.00(m, 1H), 6.92- 6.90(m, 1H), 6.48(s, 1H), 4.16-4.10(m, 2H), 3.20-3.17(m, 1H), 2.26(s, 3H), 2.17- 2.15(m, 2H), 2.07- 1.96(m, 2H), 1.83- 1.72(m, 2H), 1.69- 1.65(m, 2H)
1H NMR (CDCl3): δ 7.82- 7.66(bs, 1H), 7.12- 6.75(m, 5H), 4.27- 3.99(m, 2H), 3.51- 3.30(bs, 1H), 2.75- 2.34(m, 5H), 2.20- 1.55(m, 6H)
1H NMR (CDCl3): δ 7.98(s, 1H), 7.50- 7.39(m, 3H), 7.34- 7.27(m, 2H), 7.06- 7.01(m, 1H), 6.98- 6.92(m, 1H), 6.45(s, 1H), 4.17-4.07(m, 2H), 3.05-3.01(m, 1H), 2.27(s, 3H), 2.22- 2.02(m, 2H), 2.01- 1.80(m, 2H), 1.78- 1.61(m, 2H), 1.58- 1.40(m, 2H)
1H NMR (CDCl3): δ 8.01(s, 1H), 7.36- 7.32(m, 1H), 7.27- 7.21(m, 2H), 7.13- 7.11(m, 1H), 7.05- 7.00(m, 1H), 6.96- 6.90(m, 1H), 6.51(s, 1H), 4.16-4.09(m , 2H), 3.06-3.02(m, 1H), 2.39(s, 3H), 2.28(s, 3H), 2.18-2.07(m, 2H), 2.05-1.88(m, 2H), 1.81-1.62(m, 2H), 1.58-1.44(m, 2H)
1H NMR (CDCl3): δ 7.97(s, 1H), 7.48- 7.45(m, 2H), 7.42- 7.40(m, 1H), 7.32- 7.30(m, 2H), 7.15- 7.11(m, 1H), 6.82- 6.79(m, 1H), 6.66(s, 1H), 4.18-4.14(m, 2H), 3.06-3.04(m, 1H), 2.30(s, 3H), 2.15- 2.00(m, 2H), 1.99- 1.91(m, 2H), 1.69- 1.58(m, 2H), 1.56- 1.48(m, 2H)
1H NMR (CDCl3): δ 7.97(s, 1H), 7.48- 7.44(m, 1H), 7.28- 7.17(m, 2H), 7.15- 7.11(m, 1H), 7.05- 6.97(m, 1H), 6.86- 6.80(m, 1H), 6.68(s, 1H), 4.19-4.13(m, 2H), 3.31-3.28(m, 1H), 2.48(s, 3H), 2.19- 2.07(m, 2H), 1.95- 1.88(m, 2H), 1.85- 1.70(m, 2H), 1.67- 1.54(m, 2H)
1H NMR (CDCl3): δ 7.80(s, 1H), 7.44- 7.36(m, 1H), 7.34- 7.29(m, 3H), 7.09- 7.07(m, 1H), 6.68- 6.64(m, 2H), 4.20- 4.14(m, 2H), 3.82(s, 3H), 3.04-3.00(m, 1H), 2.26(s, 3H), 2.14- 2.00(m, 2H), 2.13- 1.87(m, 2H), 1.79- 1.59(m, 2H), 1.56-1.40 (m, 2H)
1H NMR (CDCl3): δ 7.91 (s, 1H), 7.46-7.42(m, 2H), 7.38-7.29(m, 2H), 7.22-7.18(m, 1H), 7.02(s, 1H), 6.54(s, 1H), 4.18-4.10(m, 2H), 3.21-3.10(m, 1H), 2.32(s, 3H), 2.31(s, 3H), 2.22-2.16(m, 2H), 2.12-1.91(m, 2H), 1.81-1.68(m, 2H), 1.65-1.48(m, 2H)
1H NMR (CDCl3): δ 7.92 (s, 1H), 7.44-7.38(m, 2H), 7.20-7.15(m, 1H), 7.13-7.09(m, 1H), 7.07-6.97(m, 2H), 6.55(s, 1H), 4.17- 4.07(m, 2H), 3.30- 3.23(m, 1H), 2.49(s, 3H), 2.37(s, 3H), 2.15-2.05(m, 2H), 1.93-1.90(m, 2H), 1.79-1.76(m, 2H), 1.63-1.61(m, 2H)
1H NMR (CDCl3): δ 8.06- 7.93(m, 1H), 7.75(d, 8.4Hz, 2H), 7.49(d, J = 8.0, 2H), 7.44- 7.33(m, 1H), 7.21- 7.09(m, 2H), 6.42- 6.38(bs, 1H), 4.22- 4.07(m, 2H), 3.10 2.98(m, 1H), 2.29(s, 3H), 2.19-1.85(m, 3H) 1.85-1.39(m, 5H)
1H NMR (CDCl3): δ 8.03(s, 1H), 7.39- 7.28(m, 3H), 7.23- 7.11(m, 3H), 7.05- 7.01(m, 1H), 6.67(s, 1H), 4.23-4.14(m, 2H), 3.66-3.60(m, 2H), 3.17-3.03(m, 1H), 2.75-2.71(m, 2H), 2.32(s, 3H), 2.05-1.96 (m, 2H), 1.94-1.83(m, 2H), 1.81-1.69(m, 2H), 1.61-1.46(m, 2H)
1H NMR (CDCl3): δ 8.11(s, 1H), 7.28(t, 1H, J = 7.2), 7.23- 7.19(m, 2H), 7.19- 7.17(m, 1H), 7.07(t, 1H, J = 7.6), 6.81(t, 2H, J = 2.8), 6.74(s, 1H), 4.18-4.14(m, 2H), 3.09-3.01(m, 1H), 3.00(s, 9H), 2.14(s, 3H), 2.12-2.06(m, 2H), 2.01-1.92(m, 2H), 1.79-1.66(m, 2H), 1.58-1.46(m, 2H)
1H NMR (CDCl3): δ 8.04(s, 1H), 7.48- 7.46(m, 2H), 7.35- 7.27(m, 3H), 7.24- 7.19(m, 1H), 7.12- 7.08(m, 1H), 6.67(s, 1H), 4.17-4.13(m, 2H), 3.10-3.07(m, 1H), 2.30(s, 3H), 2.18- 1.99(m, 2H), 1.98- 1.90(m, 2H), 1.80- 1.62(m, 2H), 1.44- 1.36(m, 2H), 1.36(s, 9H)
1H NMR (CDCl3): δ 8.11(s, 1H), 7.37(t, 1H, J = 8.0), 7.22- 7.20(m, 2H), 7.13(t, 1H, J = 7.6), 7.06(d, 1H, J = 7.6), 6.86- 6.78(m, 2H), 4.15- 4.11(m, 2H), 3.08- 3.04(s, 1H), 2.25(s, 3H), 2.17-2.10(m, 2H), 2.02-1.90(m, 2H), 1.78-1.66(m, 2H), 1.58-1.46(m, 2H)
1H NMR (CD3OD): δ 7.83(s, 1H), 7.29- 7.15(m, 3H), 7.06- 7.00(m, 2H), 6.80- 6.77(m, 2H), 4.14- 4.10(m, 2H), 3.30(s, 3H), 3.20-3.15(m, 1H), 2.45-2.43(m, 2H), 2.10-2.00(m, 2H), 1.84-1.81(m, 2H), 1.62-1.47(m, 2H)
1H NMR (CDCl3): δ 7.96(s, 1H), 7.42- 7.36(m, 3H), 7.31- 7.14(m, 3H), 6.99- 6.97(m, 1H), 6.45(s, 1H), 4.15-4.08(m, 2H), 3.26-3.22(s, 1H), 2.39(s, 3H), 2.35- 2.25(m, 2H), 2.09- 1.96(m, 2H), 1.88- 1.64(m, 2H), 1.60- 1.53(m, 2H)
1H NMR (CDCl3): δ 8.01(s, 1H), 7.51- 7.48(m, 1H), 7.41- 7.34(m, 2H), 7.28- 7.13(m, 3H), 6.96- 6.93(m, 1H), 6.26(s, 1H), 4.18-4.05(m, 2H), 3.22-3.20(s, 1H), 2.37(s, 3H), 2.35- 2.28(m, 2H), 2.07- 1.93(m, 2H), 1.84- 1.63(m, 2H), 1.57- 1.52(m, 2H)
1H NMR (CDCl3): δ 7.84(s, 1H), 7.39- 7.33(m, 1H), 7.31- 7.12(m, 4H), 7.05- 7.01(m, 1H), 6.96- 6.90(m, 1H), 4.21- 4.09(m, 2H), 3.21- 3.14(s, 1H), 2.40(s, 3H), 2.36-2.26(m, 2H), 2.13-1.96(m, 2H) 1.84-1.66(m, 2H), 1.64-1.53(m, 2H)
1H NMR (CDCl3): δ 8.11(s, 1H), 7.35- 7.27(m, 1H), 7.23- 7.21(m, 2H), 7.18(s, 1H), 7.13-7.09(m, 1H), 6.99(s, 1H), 6.74(s, 1H), 4.17-4.12(m, 2H), 3.12-3.09(m, 1H), 2.39(s, 3H), 2.30(s, 3H), 2.23-2.11(m, 2H), 2.01-1.98(m, 2H), 1.79-1.66(m, 2H), 1.58-1.46(m, 2H), 1.32(m, 9H)
1H NMR (CDCl3): δ 7.99(s, 1H), 7.60- 7.58(m, 1H), 7.56- 7.53(m, 1H), 7.41- 7.36(m, 1H), 7.32- 7.27(m, 1H), 7.20- 7.14(m, 2H), 6.37(s, 1H), 4.18-4.13(m, 2H), 3.14-3.12(m, 1H), 2.34(s, 3H), 2.34- 2.21(m, 2H), 2.06- 1.93(m, 2H), 1.76- 1.68(m, 2H), 1.64- 1.46(m, 2H)
1H NMR (CDCl3): δ 8.04(s, 1H), 7.30(t, 1H, J = 8.0), 7.15- 7.12(m, 2H), 7.07- 7.03(m, 2H), 6.82(d, 1H, J = 8.4), 6.59(s, 1H), 4.18-4.09(m, 2H), 3.08-3.04(m, 1H), 2.30(s, 3H), 2.25-2.10 (m, 2H), 2.08-1.91(m, 2H), 1.81-1.57(m, 2H), 1.56-1.43(m, 2H)
1H NMR (CD3OD): δ 7.84(s, 1H), 7.31- 7.18(m, 3H), 7.06- 7.02(m, 2H), 6.82- 6.79(m, 2H), 4.11- 4.08(m, 2H), 3.30(s, 3H), 3.21-3.18(m, 1H), 2.45-2.43(m, 2H), 2.08-2.01(m, 2H), 1.84-1.82(m, 2H), 1.61-1.45(m, 2H)
1H NMR (CDCl3): δ 8.06- 7.93(bs, 1H), 7.38- 7.34(m, 1H), 7.23- 7.19(m, 3H), 7.17- 7.10(m, 2H), 6.51- 6.44(bs, 1H), 4.20- 4.12(m, 2H), 3.16- 3.07(bs, 1H), 2.33(s, 3H), 2.25-2.13(m, 2H), 2.07-1.92(m, 2H), 1.84-1.65(m, 2H), 1.65-1.46(m, 2H)
1H NMR (CDCl3): δ 7.98(s, 1H), 7.29- 7.28(m, 1H), 7.17- 7.14(m, 1H), 7.08- 7.03(m, 2H), 6.90(dd, 1H, J = 8.8, J = 2.8), 6.33(s, 1H), 4.17- 4.13(m, 2H), 3.05- 3.03(m, 1H), 2.28(s, 3H), 2.08-2.03(m, 2H), 2.02-1.89(m, 2H), 1.79-1.63(m, 2H), 1.60-1.42(m, 2H)
1H NMR (CDCl3): δ 7.94(s, 1H), 7.54(d, 1H, J = 8.4), 7.44(d, 1H, J = 2.0), 7.19(dd, 1H, J = 8.4, J = 2.0), 7.09-7.05(m, 1H), 6.91(dd, 1H, J = 8.4, J = 2.8), 6.38(s, 1H), 4.20-4.14(m, 2H), 3.17-3.16(m, 1H), 2.36(s, 3H), 2.07- 1.96(m, 2H), 1.83- 1.80(m, 2H), 1.77- 1.71(m, 2H), 1.58- 1.54(m, 2H)
1H NMR (CDCl3): δ 8.01(s, 1H), 7.38(t, 1H, J = 8.0), 7.25- 7.23(m, 1H), 7.16- 7.13(m, 2H), 7.05- 7.00(m, 1H), 6.95- 6.92(m, 1H), 6.53(s, 1H), 4.17-4.12(m, 2H), 3.05-3.03(m, 1H), 2.68(q, 2H, J = 7.6), 2.28(s, 3H), 2.16- 2.02(m, 2H), 2.00- 1.88(m, 2H), 1.78- 1.62(m, 2H), 1.59- 1.41(m, 2H), 1.25(t, 3H, J = 7.6)
1H NMR (CDCl3): δ 8.01(s, 1H), 7.03- 6.98(m, 2H), 6.93- 6.89(m, 2H), 6.55(s, 1H), 4.20-4.14(m, 2H), 3.03-3.01(m, 1H), 2.38(s, 6H), 2.35(s, 3H), 2.09-2.04(m, 2H), 2.03-1.90(m, 2H), 1.79-1.63(m, 2H), 1.59-1.44(m, 2H)
1H NMR (CDCl3): δ 8.02(s, 1H), 7.25- 7.21(m, 2H), 7.03- 6.99(m, 1H), 6.92- 6.89(m, 1H), 6.71- 6.67(m, 2H), 6.60(s, 2H), 4.16-4.12(m, 2H), 3.04-3.01(m, 1H), 2.28(s, 3H), 2.02- 1.97(m, 2H), 1.96- 1.89(m, 2H), 1.78- 1.63(m, 2H), 1.57- 1.41(m, 2H)
1H NMR (CDCl3): δ 8.29(d, 1H, J = 8.8), 7.59(d, 1H, J = 8.8), 7.52-7.49(m, 2H), 7.46-7.44(m, 2H), 7.36-7.34(m, 2H), 6.78(s, 1H), 4.19- 4.16(m, 2H), 3.12- 3.10(m, 1H), 2.33(s, 3H), 2.17-2.05(m, 2H), 2.03-1.93(m, 2H), 1.78-1.64(m, 2H), 1.53-1.51(m, 2H)
1H NMR (CDCl3): δ 8.27(d, 1H, J = 8.4), 7.59(d, 1H, J = 8.8), 7.41(d, 1H, J = 1.2), 7.34-7.31(m, 2H), 7.22-7.18(m, 2H), 6.70(s, 1H), 4.22- 4.16(m, 2H), 3.26- 3.24(m, 1H), 2.41(s, 3H), 2.35-2.29(m, 2H), 2.13-1.98(m, 2H), 1.88-1.77(m, 2H), 1.62-1.59(m, 2H)
1H NMR (CDCl3): δ 8.29(d, 1H, J = 8.8), 7.61(d, 1H, J = 8.8), 7.51-7.45(m, 1H), 7.43(s, 1H), 7.18- 7.13(m, 2H), 7.08- 7.06(m, 1H), 6.71(s, 1H), 4.21-4.17(m, 2H), 3.12-3.10(m, 1H), 2.33(s, 3H), 2.19- 2.15(m, 2H), 2.07- 1.92(m, 2H), 1.74- 1.71(m, 2H), 1.53- 1.50(m, 2H)
1H NMR (CDCl3): δ 8.26(d, 1H, J = 8.8), 7.62(d, 1H, J = 8.8), 7.43(s, 1H), 6.93- 6.89(m, 3H), 6.78(s, 1H), 4.24-4.19(m, 2H), 3.28-3.21(m, 1H), 2.45(s, 3H), 2.15- 2.04(m, 2H), 1.89- 1.87(m, 2H), 1.82- 1.80(m, 2H), 1.67- 1.63(m, 2H)
1H NMR (CDCl3): δ 8.27(d, 1H, J = 8.4), 7.61(d, 1H, J = 8.8), 7.47-7.43(m, 3H), 7.35(s, 1H), 7.25- 7.23(m, 1H), 6.75(s, 1H), 4.23-4.17(m, 2H), 3.34-3.32(m, 1H), 2.42(s, 3H), 2.11- 2.05(m, 2H), 2.02- 1.91(m, 2H), 1.90- 1.83(m, 2H), 1.83- 1.80(m, 2H)
1H NMR (CDCl3): δ 7.91(s, 1H), 7.22- 7.20(m, 1H), 7.15- 7.13(m, 1H), 7.10- 7.05(m, 1H), 6.99- 6.97(m, 1H), 6.92(dd, 1H, J = 8.8, J = 2.8), 6.44(s, 1H), 4.21- 4.14(m, 2H), 3.22- 3.19(m, 1H), 2.40(s, 3H), 2.32-2.28(m, 2H), 2.10-2.02(m, 2H), 1.86-1.59(m, 2H), 1.26-1.22(m, 2H)
1H NMR (CDCl3): δ 7.91(s, 1H), 7.39(dd, 1H, J = 7.2, J = 2.0), 7.23-7.19(m, 2H), 7.08-7.04(m, 1H), 6.90(dd, 1H, J = 8.4, J = 2.8), 6.37(s, 1H), 4.18-4.13(m, 2H), 3.14-3.10(m, 1H), 2.33(s, 3H), 2.23- 2.16(m, 2H), 2.06- 1.91(m, 2H), 1.82- 1.65(m, 2H), 1.60- 1.51(m, 2H)
1H NMR (CDCl3): δ 7.81(s, 1H), 7.47- 7.43(m, 1H), 7.19- 7.11(m, 2H), 7.11- 6.95(m, 1H), 6.90(dd, 1H, J = 8.8, J = 3.2), 6.62(s, 1H), 4.14- 4.04(m, 2H), 3.21- 3.16(m, 1H), 2.37(s, 3H), 2.04-1.95(m, 2H), 1.84-1.69(m, 2H), 1.67-1.61(m, 1H), 1.57-1.48(m, 2H)
1H NMR (CDCl3): δ 7.90(s, 1H), 7.41- 7.40(m, 1H), 7.25- 7.22(m, 2H), 7.10- 7.05(m, 1H), 6.91(dd, 1H, J = 8.8, J = 2.8), 6.38(s, 1H), 4.20- 4.16(m, 2H), 3.16- 3.12(m, 1H), 2.36(s, 3H), 2.23-2.21(m, 2H), 2.09-1.94(m, 2H), 1.80-1.64(m, 2H), 1.56-1.52(m, 2H)
1H NMR (CDCl3): δ 7.81(s, 1H), 7.31- 7.30(m, 1H), 7.19- 7.18(m, 1H), 7.09- 7.04(m, 1H), 6.91- 6.62(m, 1H), 6.61(s, 1H), 4.20-4.11(m, 2H), 3.26-3.22(m, 1H), 2.42-2.30(m, 4H), 2.11-1.93(m, 2H), 1.88-1.63(m, 2H), 1.61-1.54(m, 2H)
1H NMR (CDCl3): δ 7.83(s, 1H), 7.03- 6.95(m, 1H), 6.91- 6.88(m, 1H), 6.80(s, 1H), 6.73-6.66(m, 2H), 4.12-4.07(m, 2H), 3.21-3.17(m, 1H), 2.35(s, 3H), 2.28- 2.24(m, 2H), 1.82- 1.65(m, 2H), 1.62- 1.55(m, 2H), 1.25- 1.21(m, 2H)
1H NMR (CDCl3): δ 7.83(s, 1H), 7.25- 7.20(m, 1H), 7.05- 6.92(m, 3H), 6.88(dd, 1H, J = 8.8, J = 2.8), 6.57(s, 1H), 4.14- 4.06(m, 2H), 3.22- 3.17(m, 1H), 2.40(s, 3H), 2.39-2.29(m, 2H), 2.10-1.97(m, 2H), 1.86-1.66(m, 2H), 1.65-1.54(m, 2H)
1H NMR (CDCl3): δ 7.99(s, 1H), 7.22- 7.20(m, 1H), 7.08- 6.97(m, 3H), 6.90(dd, 1H, J = 9.2, J = 2.8), 6.57(s, 1H), 4.15- 4.13(m, 2H), 3.16- 3.12(m, 1H), 2.31(s, 3H), 2.29(s, 6H), 2.02-2.17(m, 2H), 2.00-1.89(m, 2H), 1.76-1.55(m, 2H), 1.53-1.42(m, 2H)
1H NMR (CDCl3): δ 7.93(s, 1H), 7.46- 7.40(m, 2H), 7.39- 7.36(m, 1H), 7.35- 7.33(m, 2H), 6.89(dd, 1H, J = 8.8, J = 2.8), 6.77(d, 1H, J = 2.8), 6.38(s, 1H), 4.15- 4.10(m, 2H), 3.86(s, 3H), 3.14-3.11(m, 1H), 2.35(m, 3H), 2.26- 2.16(m, 2H), 2.06- 1.91(m, 2H), 1.82- 1.62(m, 2H), 1.60- 1.45(m, 2H)
1H NMR (CDCl3): δ 7.82(s, 1H), 7.42- 7.39(m, 1H), 7.14- 7.10(m, 1H), 7.07- 7.05(m, 2H), 6.90(dd, 1H, J = 8.8, J = 3.2), 6.75(d, 1H, J = 3.2), 6.37(s, 1H), 4.17- 4.13(m, 2H), 3.79(s, 3H), 3.21-3.18(m, 1H), 2.38(s, 3H), 2.30- 2.26(m, 2H), 2.09- 1.99(m, 2H), 1.74- 1.70(m, 2H), 1.56- 1.53(m, 2H)
1H NMR (CDCl3): δ 7.72(s, 1H), 7.28- 7.26(m, 1H), 6.92- 6.79(m, 3H), 6.74- 6.73(m, 1H), 6.29(s, 1H), 4.15-4.10(m, 2H), 3.75(s, 3H), 3.15- 3.10(m, 1H), 2.34(s, 3H), 2.27-2.25(m, 2H), 2.06-1.96(m, 2H), 1.78-1.69(m, 2H), 1.63-1.50(m, 2H)
1H NMR (CDCl3): δ 7.82(s, 1H), 7.38- 7.34(m, 2H), 7.23- 7.21(m, 2H), 6.90(dd, 1H, J = 9.2, J = 2.8), 6.74(d, 1H, J = 2.8), 6.28(s, 1H), 4.17- 4.12(m, 2H), 3.78(s, 3H), 3.16-3.14(m, 1H), 2.35(s, 3H), 2.23- 2.18(m, 2H), 2.21- 1.93(m, 2H), 1.79- 1.64(m, 2H), 1.60- 1.50(m, 2H)
1H NMR (CDCl3): δ 7.35(m, 1H), 7.23- 7.20(m, 2H), 6.90(dd, 1H, J = 8.8, J = 2.8), 6.72-6.72(m, 1H), 6.58(s, 1H), 4.16- 4.08(m, 2H), 3.75(s, 3H), 3.28-3.26(m, 1H), 2.43(s, 3H), 2.40- 2.38(m, 2H), 2.08- 2.02(m, 2H), 1.85- 1.72(m, 2H), 1.60- 1.57(m, 2H)
1H NMR (CDCl3): δ 7.70(s, 1H), 7.39- 7.38(m, 1H), 7.21- 7.19(m, 2H), 6.90(dd, 1H, J = 8.8, J = 2.8), 6.72-6.71(m, 1H), 6.21(s, 1H), 4.15- 4.09(m, 2H), 3.76(s, 3H), 3.13-3.11(m, 1H), 2.37(s, 3H), 2.30- 2.23(m, 2H), 2.02- 1.97(m, 2H), 1.79- 1.71(m, 2H), 1.62- 1.56(m, 2H)
1H NMR (CDCl3): δ 8.04(s, 1H), 7.48- 7.45(m, 2H), 7.43- 7.39(m, 1H), 7.32- 7.28(m, 3H), 7.23- 7.18(m, 1H), 6.56(s, 1H), 4.16-4.12(m, 2H), 3.06-3.02(m, 1H), 2.28(s, 3H), 2.12- 1.96(m, 2H), 1.94- 1.87(m, 2H), 1.76- 1.64(m, 2H), 1.57- 1.44(m, 2H)
1H NMR (CDCl3): δ 8.03(s, 1H), 7.44(q, 1H, J = 8.0), 7.31(dd, 1H, J = 8.8, J = 2.4), 7.14-7.10(m, 2H), 7.05-7.03(m, 1H), 6.49(s, 1H), 4.17- 4.13(m, 2H), 3.03- 3.01(m, 2H), 2.29(s, 3H), 2.13-1.98(m, 2H), 1.97-1.88(m, 2H), 1.77-1.64(m, 2H), 1.59-1.42(m, 2H)
1H NMR (CDCl3): δ 8.02(s, 1H), 7.31- 7.28(m, 3H), 7.18- 7.14(m, 3H), 6.44(s, 1H), 4.17-4.13(m, 2H), 3.04-3.01(m, 1H), 2.28(s, 3H), 2.10- 2.00(m, 2H), 1.98- 1.87(m, 2H), 1.78- 1.65(m, 2H), 1.57- 1.44(m, 2H)
1H NMR (CDCl3): δ 7.99(s, 1H), 7.34- 7.31(m, 2H), 7.17- 7.16(m, 1H), 6.88- 6.84(m, 2H), 6.51(s, 1H), 4.18-4.10(m, 2H), 3.16-3.13(m, 1H), 2.36(s, 3H), 2.32- 2.29(m, 2H), 2.08- 1.96(m, 2H), 1.82- 1.61(m, 2H), 1.57- 1.49(m, 2H)
1H NMR (CDCl3): δ 8.01(s, 1H), 7.43- 7.38(m, 2H), 7.32- 7.30(m, 2H), 7.23- 7.21(m, 1H), 7.17(d, 1H, J = 2.4), 6.47(s, 1H), 4.18-4.13(m, 2H), 3.06-3.04(m, 1H), 2.25(s, 3H), 2.19- 2.06(m, 2H), 2.05- 1.90(m, 2H), 1.80- 1.59(m, 2H), 1.58- 1.44(m, 2H)
1H NMR (CDCl3): δ 7.98(s, 1H), 7.41(s, 1H), 7.33(dd, 1H, J = 8.8, J = 2.4), 7.23- 7.22(m, 2H), 7.15(d, 1H, J = 2.4), 6.39(s, 1H), 4.19-4.14(m, 2H), 3.09-3.05(m, 1H), 2.30(s, 3H), 2.19- 2.07(m, 2H), 2.04- 1.91(m, 2H), 1.77- 1.61(m, 2H), 1.59- 1.43(m, 2H)
1H NMR (CDCl3): δ 7.99(s, 1H), 7.33(dd, 1H, J = 8.8, J = 2.4), 7.21-7.13(m, 3H), 6.96(dd, 1H, J = 8.8, J = 2.4), 6.46(s, 1H), 4.20-4.12(m, 2H), 3.11-3.07(m, 1H), 2.32(s, 3H), 2.20- 2.14(m, 2H), 2.06- 1.91(m, 2H), 1.79- 1.62(m, 2H), 1.60- 1.45(m, 2H)
1H NMR (CDCl3): δ 7.98(s, 1H), 7.39- 7.37(m, 1H), 7.32- 7.26(m, 1H), 7.23- 7.21(m, 2H), 7.19(d, 1H, J = 2.8), 6.41(s, 1H), 4.17-4.13 (m, 2H), 3.06-3.03(m, 1H), 2.26(s, 3H), 2.39- 2.10(m, 2H), 2.03- 1.89(m, 2H), 1.80- 1.59(m, 2H), 1.57- 1.43(m, 2H)
1H NMR (CDCl3): δ 8.00- 7.93(m, 2H), 7.41- 7.37(t, 1H, J = 15.2), 7.29-7.27(d, 1H, J = 8.0), 7.23-7.15(m, 3H), 6.51(s, 1H), 4.08-3.97(m, 2H), 2.60-2.56(t, 1H, J = 17.2), 2.49-2.45(m, 3H), 2.29-2.24(m, 4H), 1.96-1.91(m, 1H), 1.48-1.43(m, 1H)
1H NMR (CD3OD): δ 7.19- 7.17(m, 1H), 6.92- 6.90(m, 2H), 6.85- 6.76(m, 2H), 6.72- 6.71(m, 1H), 4.10- 4.02(m, 2H), 3.70- 3.61(m, 1H), 3.16- 3.10(m, 2H), 2.83(s, 3H), 2.27-2.13(m, 2H), 2.13-2.02(m, 2H), 1.77-1.72(m, 2H)
1H NMR (CD3OD): δ 7.33- 7.32(m, 1H), 7.27- 7.23(m, 1H), 7.17- 7.15(m, 1H), 7.05- 7.01(m, 1H), 6.82- 6.79(m, 1H), 6.72- 6.71(m, 1H), 4.11- 4.07(m, 2H), 3.50- 3.47(m, 1H), 3.04- 3.01(m, 2H), 2.70(s, 3H), 2.20-2.16(m, 2H), 1.95-1.90(m, 2H), 1.75-1.70(m, 2H)
1H NMR (CD3OD): δ 7.44- 7.42(m, 1H), 7.27- 7.22(m, 2H), 7.16- 7.14(m, 1H), 6.77- 6.75(m, 1H), 6.70- 6.69(m, 1H), 4.08- 4.02(m, 2H), 3.64- 3.57(m, 1H), 3.13- 3.09(m, 2H), 2.86(s, 3H), 2.27-2.22(m, 2H), 1.97-1.93(m, 2H), 1.75-1.70(m, 2H)
1H NMR (CDCl3): δ 8.17- 7.98(bs, 1H), 7.60- 7.29(m, 6H), 7.26- 7.06(m, 2H), 6.78- 6.61(bs, 1H), 4.17- 3.94(m, 2H), 3.09- 2.81(m, 3H), 2.75- 2.59(m, 1H), 2.56- 2.33(m, 2H), 1.98- 1.80(m, 1H), 1.54- 1.35(m, 1H)
1H NMR (CDCl3): δ 8.07- 7.89(bs, 1H), 7.58- 7.32(m, 6H), 7.32- 7.13(m, 2H), 7.01- 6.85(bs, 1H), 4.28- 3.98(m, 3H), 3.47- 3.17(m, 3H), 3.13- 2.95(m, 1H), 2.80- 2.62(m, 1H), 2.25- 2.08(m, 1H), 1.89- 1.70(m, 1H)
1H NMR (CDCl3): δ 8.10- 7.93(bs, 1H), 7.45- 7.30(m, 1H), 7.21- 7.08(m, 2H), 6.98- 6.79(m, 3H), 6.67- 6.51(bs, 1H), 4.15- 3.90(m, 2H), 3.11- 2.76(m, 3H), 2.71- 2.53(m, 8H), 2.48- 2.29(m, 1H), 2.02- 2.72(m, 2H), 1.49- 1.29(m, 1H)
1H NMR (CDCl3): δ 8.10- 7.89(m, 1H), 7.49- 7.30(m, 1H), 7.22- 7.04(m, 2H), 6.98- 6.75(m, 3H), 6.68- 6.50(bs, 1H), 4.19- 3.85(m, 2H), 3.12- 2.75(m, 3H), 2.72- 2.52(bs, 1H), 2.52- 2.27(m, 1H), 2.07- 1.72(m, 2H), 1.50- 1.31(m, 1H)
1H NMR (CDCl3): δ 7.81(s, 1H), 7.45- 7.36(m, 3H), 7.33- 7.26(m, 2H), 7.06- 7.01(m, 1H), 6.97- 6.94(m, 1H), 4.12- 4.06(m, 2H), 3.35- 3.27(m, 1H), 3.23- 3.16(m, 1H), 3.05- 3.02(m, 1H), 2.69- 2.65(m, 1H), 2.17- 2.12(m, 1H), 1.82- 1.78(m, 2H)
1H NMR (CDCl3): δ 7.82(s, 1H), 7.35- 7.31(m, 1H), 7.20- 7.18(m, 1H), 7.18- 7.14(m, 1H), 7.13- 7.11(m, 1H), 7.07- 6.98(m, 1H), 6.95- 6.92(m, 1H), 4.13- 4.07(m, 2H), 3.38- 3.33(m, 2H), 3.25- 3.22(m, 1H), 3.09- 3.05(m, 1H), 2.69- 2.65(m, 1H), 2.38(s, 3H), 2.15-2.13(m, 1H), 1.80-1.76(m, 1H)
1H NMR (CDCl3): δ 7.98- 7.79(bs, 1H), 7.14- 7.00(m, 1H), 7.00- 6.78(m, 4H), 6.61- 6.45(bs, 1H), 4.18- 3.90(m, 2H), 3.13- 2.80(m, 3H), 2.70- 2.57(m, 1H), 2.51- 2.21(m, 2H), 1.94- 1.80(m, 1H), 1.49- 1.35(m, 1H)
1H NMR (CDCl3): δ 7.96- 7.77(bs, 1H), 7.13- 6.99(m, 1H), 6.99- 6.76(m, 4H), 6.68- 6.50(bs, 1H), 4.15- 3.92(m, 2H), 3.16- 2.90(bs, 3H), 2.90- 2.30(m, 3H), 1.99- 1.81(m, 1H), 1.53- 1.35(m, 1H)
1H NMR (CDCl3): δ 7.77 (s, 1H), 7.44-7.40(m, 2H), 7.37-7.31(m, 2H), 7.20-7.13(m, 2H), 7.04(s, 1H), 6.85(s, 1H), 4.13-4.04(m, 2H), 2.78-2.62(m, 3H), 2.32(s, 3H), 2.16- 2.09(m, 2H), 2.03(s, 1H), 1.79-1.70(m, 2H)
1H NMR (CDCl3): δ 7.84 (s, 1H), 7.43-7.38(m, 1H), 7.17-7.08(m, 2H), 7.04-7.02(m, 2H), 7.01(s, 1H), 6.55(s, 1H), 4.08-3.97(m, 2H), 2.47-2.33(m, 3H), 2.32(s, 3H), 1.94- 1.80(m, 2H), 1.51- 1.40(m, 2H)
1H NMR (CDCl3): δ 8.13- 7.94(m, 1H), 7.41- 7.23(m, 3H), 7.20- 7.02(m, 4H), 6.75- 6.57(bs, 1H), 4.23- 4.04(m, 1H), 4.02- 3.85(m, 1H), 3.47- 3.30(m, 1H), 3.02- 2.81(m, 2H), 2.57- 2.25(bs, 1H), 1.95- 1.59(m, 3H), 1.50- 1.32(m, 1H)
1H NMR (CDCl3): δ 8.13- 7.94(bs, 1H), 7.55- 7.27(m, 6H), 7.26- 7.03(m, 2H), 6.77- 6.59(bs, 1H), 4.18- 3.94(m, 2H), 3.00- 2.57(m, 4H), 2.54- 2.49(m, 1H), 2.47(s, 3H), 2.10-1.98(m, 1H) 1.67-1.55(m, 1H)
1H NMR (CDCl3): δ 8.09- 7.94(bs, 1H), 7.56- 7.31(m, 6H), 7.30- 7.12(m, 2H), 6.86- 6.72(bs, 1H), 4.19- 4.02(m, 1H), 3.41- 3.05(m, 3H), 2.97- 2.77(m, 2H), 2.74(s, 3H), 2.29-2.15(m, 1H), 1.89-1.74(m, 1H)
1H NMR (CDCl3): δ 8.08- 7.95(bs, 1H), 7.42- 7.33(m, 1H), 7.21- 7.08(m, 2H), 6.98- 6.79(m, 3H), 6.59- 6.48(bs, 1H), 4.13- 3.95(m, 2H), 2.69- 2.43(m, 3H), 2.40- 2.14(m, 5H), 2.05- 1.90(m, 1H), 1.57- 1.42(m, 1H)
1H NMR (CDCl3): δ 8.08- 7.95(bs, 1H), 7.42- 7.33(m, 1H), 7.21- 7.08(m, 2H), 6.98- 6.79(m, 3H), 6.59- 6.48(bs, 1H), 4.13- 3.95(m, 2H), 2.69- 2.43(m, 3H), 2.40- 2.14(m, 5H), 2.05- 1.90(m, 1H), 1.57- 1.42(m, 1H)
1H NMR (CDCl3): δ 7.98(s, 1H), 7.49- 7.39(m, 3H), 7.34- 7.32(m, 2H), 7.06- 7.01(m, 1H), 6.94- 6.91(m, 1H), 6.49(s, 1H), 4.08-3.96(m, 2H), 2.61-2.57(m, 1H), 2.53-2.44(m, 3H), 2.30(s, 3H), 2.27- 2.22(m, 1H), 1.98- 1.89(m, 1H), 1.49- 1.41(m, 1H)
1H NMR (CDCl3): δ 7.97(s, 1H), 7.37- 7.33(m, 1H), 7.30- 7.21(m, 2H), 7.13- 7.11(m, 1H), 7.04- 7.00(m, 1H), 6.95- 6.91(m, 1H), 6.58(s, 1H), 4.08-3.98(m, 2H), 2.71-2.66(m, 1H), 2.59-2.46(m, 3H), 2.46-2.33(m, 7H), 2.01-1.97(m, 1H), 1.55-1.48(m, 1H)
1H NMR (CDCl3): δ 7.97- 7.81(bs, 1H), 7.13- 7.01(m, 1H), 6.99- 6.78(m, 4H), 6.57- 6.41(bs, 1H), 4.13- 3.94(m, 2H), 2.70- 2.42(m, 4H), 2.05- 2.88(m, 1H), 1.58- 1.41(m, 4H)
1H NMR (CDCl3): δ 7.97- 7.78(bs, 1H), 7.14- 7.00(m, 1H), 6.99- 6.78(m, 4H), 6.63- 6.45(bs, 1H), 4.14- 3.93(m, 2H), 2.71- 2.42(m, 4H), 2.40- 2.23(bs, 4H), 2.05- 1.88(m, 1H), 1.59- 1.41(m, 1H)
1H NMR (CDCl3): δ 7.89 (s, 1H), 7.47-7.43(m, 2H), 7.39-7.31(m, 2H), 7.22-7.13(m, 2H), 7.02(s, 1H), 6.63(s, 1H), 4.09-4.01(m, 2H), 2.67-2.58(s, 3H), 2.32(s, 3H), 2.11-2.01(m, 2H), 1.65-1.58(m, 2H)
1H NMR (CDCl3): δ 7.88 (s, 1H), 7.44-7.38(m, 1H), 7.17-7.10(m, 2H), 7.09-7.05(m, 2H), 7.01(s, 1H), 6.55(s, 1H), 4.09-3.98(m, 2H), 2.38(s, 3H), 2.32(s, 3H), 2.61-2.40(m, 3H), 2.15-1.97(m, 2H), 1.56-1.51(m, 2H)
1H NMR (CDCl3): δ 8.13- 7.96(m, 1H), 7.41- 7.23(m, 3H), 7.20- 7.02(m, 4H), 6.62- 6.45(bs, 1H), 4.24- 3.97(m, 2H), 3.10- 2.96(m, 1H), 2.50- 2.27(m, 4H), 2.27- 2.13(m, 1H) 1.96- 1.80(m, 1H), 1.80- 1.51(m, 3H)
1H NMR (CDCl3): δ 8.13- 7.96(bs, 1H), 7.41- 7.30(m, 2H), 7.30- 7.03(m, 5H), 6.71- 6.59(bs, 1H), 4.13- 3.95(m, 2H), 2.72- 2.59(m, 1H), 2.59- 2.43(m, 3H), 2.40(s, 3H), 2.14-2.22(m, 4H), 2.06-1.87(m, 1H), 1.55-1.42(m, 1H)
1H NMR (CDCl3): δ 8.15- 7.99(bs, 1H), 7.46- 7.29(m, 2H), 7.28- 7.02(m, 5H), 6.74- 6.58(bs, 1H), 4.15- 3.93(m, 2H), 2.70- 2.43(m, 4H), 2.40(s, 3H), 2.31(s, 3H), 2.15-2.17(m, 1H) 2.03- 1.86(m, 1H), 1.57- 1.40(m, 1H)
1H NMR (CDCl3): δ 8.13- 7.96(bs, 1H), 7.54- 7.26(m, 6H), 7.25- 7.02(m, 2H), 6.72- 6.55(bs, 1H), 4.15- 3.92(m, 2H), 2.91- 2.69(m, 1H), 2.69- 2.35(m, 5H), 2.33- 2.17(m, 1H), 2.04- 1.87(m, 1H) 1.60- 1.42(m, 1H), 1.00(t, 3H, J = 7.2)
1H NMR (CDCl3): δ 8.15- 7.97(bs, 1H), 7.55- 7.27(m, 6H), 7.24- 7.05(m, 2H), 6.72- 6.59(bs, 1H), 4.14- 3.94(m, 2H), 2.92- 2.71(bs, 1H), 2.71- 2.39(m, 5H), 2.38- 2.22(m, 1H), 2.04- 1.86(m, 1H), 1.59- 1.44(m, 1H), 1.11(t, 3H, J = 7.2)
1H NMR (CDCl3): δ 8.13- 8.00(bs, 1H), 7.42- 7.27(m, 2H), 7.25- 7.03(m, 5H), 6.69- 6.59(bs, 1H), 4.13- 3.95(m, 2H), 2.80- 2.68(m, 1H), 2.68- 2.32(m, 9H), 2.30- 2.17(m, 1H), 2.03- 1.89(m, 1H), 1.58- 1.41(m, 1H), 1.18- 1.04(t, 3H, J = 7.6)
1H NMR (CDCl3): δ 8.13- 7.99(m, 1H), 7.43- 7.27(m, 2H), 7.27- 7.02(m, 5H), 6.72- 6.58(bs, 1H), 4.13- 3.94(m, 2H), 2.89- 2.66(m, 1H), 2.66- 2.15(m, 9H), 2.06- 1.87(m, 1H), 1.57- 1.40(m, 1H), 1.09(t, 3H, J = 7.6)
1H NMR (CDCl3): δ 8.15- 8.01(m, 1H), 7.54- 7.26(m, 6H), 7.22- 7.05(m, 2H), 6.72- 6.58(bs, 1H), 4.22- 4.07(m, 1H), 4.07- 3.93(m, 1H), 3.21- 3.02(m, 1H), 2.92- 2.59(m, 2H), 2.41- 2.12(m, 2H), 1.95- 1.50(m, 5H), 1.08(t, 3H, J = 7.2)
1H NMR (CDCl3): δ 8.18- 8.02(m, 1H), 7.53- 7.27(m, 6H), 7.22- 7.03(m, 2H), 6.69- 6.54(bs, 1H), 4.18- 3.83(m, 2H), 3.15- 2.95(bs, 1H), 2.71- 2.53(bs, 1H), 2.48- 2.30(m, 1H), 2.23- 2.02(m, 2H), 1.92- 1.45(m, 5H), 0.84(t, 6H, J = 6.8)
1H NMR (CDCl3): δ 7.85(s, 1H), 7.46- 7.41(m, 1H), 7.15- 7.03(m, 4H), 6.96- 6.93(m, 1H), 4.11- 4.03(m, 2H), 2.92- 2.90(m, 1H), 2.82- 2.68(m, 2H), 2.42(s, 3H), 2.12-2.10(m, 2H), 1.71-1.69(m, 2H)
1H NMR (CDCl3): δ 8.18- 7.99(m, 1H), 7.49- 7.27(m, 6H), 7.22- 7.15(m, 1H), 7.15- 7.06(m, 1H), 6.72- 6.60(bs, 1H), 4.24- 3.98(m, 2H), 3.10- 2.95(m, 1H), 2.52- 2.40(m, 1H), 2.35(s, 3H) 2.26-2.12(m, 1H), 1.97-1.50(m, 4H)
1H NMR (CDCl3): δ 8.18- 7.97(bs, 1H), 7.41- 7.28(m, 2H), 7.23- 7.01(m, 5H), 6.78- 6.62(bs, 1H), 4.12- 3.97(m, 2H), 3.05- 2.90(m, 1H), 2.52- 2.11(m, 8H), 1.95- 1.47(m, 4H)
1H NMR (CDCl3): δ 8.00(s, 1H), 7.34- 7.31(m, 1H), 7.21- 7.19(m, 1H), 7.12- 7.06(m, 2H), 7.04- 6.99(m, 1H), 6.92- 6.89(m, 1H), 6.59(s, 1H), 4.18-4.04(m, 2H), 3.06-3.02(m, 1H), 2.38(s, 3H), 2.35(s, 3H), 2.22-2.15(m, 2H), 1.92-1.76(m, 2H), 1.68-1.54(m, 2H)
1H NMR (CDCl3): δ 8.15- 8.01(m, 1H), 7.51- 7.27(m, 6H), 7.21- 7.06(m, 2H), 6.69- 6.56(bs, 1H), 4.12- 4.00(m, 1H), 3.87- 3.76(m, 1H), 3.04- 2.78(m, 3H), 2.53- 2.40(m, 1H), 1.80- 1.62(m, 4H), 1.08(d, 3H, J = 6.4), 0.99(d, 3H, J = 6.4)
1H NMR (CDCl3): δ 8.13- 7.98(m, 1H), 7.50- 7.31(m, 2H), 7.21- 7.00(m, 5H), 6.62- 6.49(bs, 1H), 4.14- 3.95(m, 2H), 2.75- 2.42(m, 4H), 2.42- 2.22(m, 4H), 2.03- 1.87(m, 1H), 1.58- 1.42(m, 1H)
1H NMR (CDCl3): δ 8.11- 7.97(bs, 1H), 7.42- 7.27(m, 3H), 7.01- 7.03(m, 4H), 6.57- 6.42(bs, 1H), 4.13- 3.92(m, 2H), 2.70- 2.41(m, 4H), 2.41- 2.20(m, 4H), 2.06- 1.94(m, 1H), 1.56- 1.41(m, 1H)
1H NMR (CDCl3) δ 8.02- 8.01(s, 1H), 7.38- 7.06(m, 5H), 6.47(s, 1H), 4.09-3.98(m, 2H), 2.62-2.58(t, 1H, J = 17.2), 2.55-2.46(m, 3H), 2.37-2.25(m, 4H), 2.04-1.91(m, 2H), 1.51-1.43(m, 1H)
1H NMR (CDCl3): δ 8.12- 7.98(bs, 1H), 7.50- 7.31(m, 2H), 7.24- 7.02(m, 5H), 6.70- 6.54(bs, 1H), 4.16- 3.97(m, 2H), 2.77- 2.65(m, 1H), 2.64- 2.47(m, 3H), 2.45- 2.28(m, 4H), 2.06- 1.93(m, 1H), 1.61- 1.47(m, 1H)
1H NMR (CDCl3): δ 8.08- 7.93(bs, 1H), 7.47- 7.27(m, 4H), 7.21- 7.05(m, 3H), 6.67- 6.53(bs, 1H), 4.15- 3.93(m, 2H), 2.80- 2.50(m, 4H), 2.50- 2.24(bs, 4H), 2.09- 1.92(m, 1H), 1.62- 1.46(m, 1H)
1H NMR (CDCl3): δ 8.07- 7.92(bs, 1H), 7.42- 7.31(m, 4H), 7.27- 7.21(m, 1H), 7.20- 7.09(m, 2H), 6.66- 6.56(bs, 1H), 4.13- 3.97(m, 2H), 2.85- 2.53(m, 4H), 2.52- 2.35(m, 4H), 2.08- 1.97(m, 1H), 1.63- 1.52(m, 1H)
1H NMR (CDCl3): δ 8.02- 7.83(bs, 1H), 7.48- 7.32(m, 2H), 7.33- 7.21(m, 2H), 7.20- 7.08(m, 2H), 6.77- 6.56(bs, 1H), 4.15- 3.95(m, 2H), 2.80- 2.54(m, 4H), 2.54- 2.30(m, 4H), 2.12- 1.92(m, 1H), 1.67- 1.49(m, 1H)
1H NMR (CDCl3): δ 8.03- 7.89(bs, 1H), 7.45- 7.33(m, 1H), 7.23- 7.07(m, 4H), 7.05- 6.95(m, 1H), 6.72- 6.56(bs, 1H), 4.16- 3.96(m, 2H), 2.78- 2.50(m, 4H), 2.50- 2.29(m, 4H), 2.10- 1.92(m, 1H), 1.65- 1.47(m, 1H)
1H NMR (CDCl3): δ 8.06- 7.96(bs, 1H), 7.49- 7.32(m, 2H), 7.25- 7.19(m, 2H), 7.18- 7.10(m, 2H), 6.65- 6.47(bs, 1H), 4.17- 3.95(m, 2H), 2.78- 2.50(m, 4H), 2.50- 2.25(m, 4H), 2.08- 1.91(m, 1H), 1.62- 1.47(m, 1H)
1H NMR (CDCl3): δ 8.03- 7.88(bs, 1H), 7.05- 6.96(m, 2H), 6.95- 6.87(m, 3H), 6.64- 6.58(bs, 1H), 4.12- 3.92(m, 2H), 2.68- 2.57(m, 1H) 2.57- 2.43(m, 3H), 2.34(s, 6H), 2.33-2.15(m, 4H), 2.00-1.77(m, 1H), 1.55-1.45(m, 1H)
1H NMR (CDCl3): δ 7.77- 7.60(bs, 1H), 7.13- 6.86(m, 3H), 6.79(s, 1H), 6.70(s, 1H), 6.53(s, 1H), 5.03- 4.50(bs, 1H), 4.33- 4.18(m, 1H), 4.18- 3.98(m, 1H), 3.08- 2.95(bs, 1H), 2.95- 2.78(bs, 1H), 2.70- 2.31(m, 5H), 2.08- 1.90(bs, 1H), 1.90- 1.70(bs, 1H)
1H NMR (CDCl3): δ 8.00- 7.85(bs, 1H), 7.38- 7.25(m, 2H), 7.20- 7.19(m, 2H), 7.03(td, 1H, J = 8.4, 2.8), 6.90(dd, 1H, J = 8.8, 2.8), 6.51-6.39(bs, 1H), 4.12-3.90(m, 2H), 2.63-2.55(m, 1H) 2.55- 2.39(m, 3H), 2.37- 2.18(m, 4H), 1.99- 1.85(m, 1H), 1.54- 1.38(m, 1H)
1H NMR (CDCl3): δ 8.02- 7.81(bs, 1H), 7.53- 7.30(m, 3H), 7.26- 7.19(m, 1H), 7.05(td, 1H, J = 8.0, 2.8), 6.91(dd, 1H, J = 8.8, 2.8), 6.54-6.45(bs, 1H), 4.13-3.86(m, 2H), 2.65-2.54(m, 1H) 2.54- 2.42(m, 3H), 2.37- 2.19(m, 4H), 2.00- 1.86(m, 1H), 1.55- 1.37(m, 1H)
1H NMR (CDCl3): δ 7.92- 7.76(bs, 1H), 7.42- 7.36(m, 1H), 7.28- 7.17(m, 2H), 7.06(td, 1H, J = 8.8, 2.8), 6.90(dd, 1H, J = 8.8, 2.8), 6.51-6.36(bs, 1H), 4.12-3.90(m, 2H), 2.63-2.55(m, 1H) 2.55- 2.39(m, 3H), 2.37- 2.18(m, 4H), 2.00- 1.85(m, 1H), 1.54- 1.38(m, 1H)
1H NMR (CDCl3): δ 7.98- 7.82(bs, 1H), 7.49- 7.38(m, 2H), 7.34- 7.20(m, 2H), 7.03(td, 1H, J = 8.4, 2.8), 6.90(dd, 1H, J = 8.8, 2.8), 6.60-6.49(bs, 1H), 4.14-3.87(m, 2H), 2.66-2.59(m, 1H) 2.59- 2.45(m, 3H), 2.42- 2.15(m, 4H), 2.04- 1.89(m, 1H), 1.57- 1.42(m, 1H)
1H NMR (CDCl3): δ 7.86- 7.65(bs, 1H), 7.58- 7.39(m, 2H), 7.26- 7.16(m, 1H), 7.04(td, 1H, J = 8.4, 3.2), 6.89(dd, 1H, J = 8.8, 3.2), 6.89-6.79(bs, 1H), 4.15-3.94(m, 2H), 2.90-2.73(m, 2H), 2.73- 2.54(m, 3H), 2.52- 2.19(m, 3H), 2.14- 1.96(m, 1H), 1.70- 1.54(m, 1H)
1H NMR (CDCl3): δ 7.97- 7.76(bs, 1H), 7.18- 7.02(m, 3H), 7.03- 6.86(m, 2H), 6.54- 6.42(bs, 1H), 4.03- 3.85(m, 2H), 2.65- 2.57(m, 1H) 2.57- 2.41(m, 3H), 2.37- 2.18(m, 4H), 2.02- 1.87(m, 1H), 1.55- 1.41(m, 1H)
1H NMR (CDCl3) δ 8.01- 7.99(m, 1H), 7.54- 7.51(d, 1H, J = 8 Hz), 7.46(m, 1H), 7.38- 7.34(m, 1H), 7.21- 7.11(m, 2H), 6.46(s, 1H), 4.09-3.98(m, 2H), 2.63-2.59(t, 1H, J = 17.2), 2.54-2.47(m, 3H), 2.36-2.26(m, 4H), 2.00-1.93(m, 1H), 1.50-1.45(m, 1H)
1H NMR (CDCl3) δ 8.01- 7.97(m, 1H), 7.43- 7.35(m, 2H), 7.26- 7.25(m, 2H), 7.18- 7.11(m, 2H), 6.46(s, 1H), 4.10-3.99(m, 2H), 2.67-2.61(t, 1H, J = 17.2), 2.57-2.50(m, 3H), 2.38-2.28(m, 4H), 2.01-1.93(m, 1H), 1.52-1.48(m, 1H)
1H NMR (CDCl3) δ 8.01- 7.99(m, 1H), 7.39- 7.35(m, 1H), 7.18- 7.11(m, 3H), 6.99- 6.97(m, 1H), 6.48(s, 1H), 4.10-3.99(m, 2H), 2.63-2.59(t, 1H, J = 17.2), 2.53-2.48(m, 3H), 2.36-2.27(m, 4H), 2.00-1.92(m, 1H), 1.51-1.46(m, 1H)
1H NMR (CDCl3) δ 8.03(m, 1H), 7.25-7.21(m, 1H), 7.03-6.98(m, 1H), 6.92-6.90(m, 1H), 6.72-6.61(m, 3H), 4.08-3.97(m, 2H), 3.80(s, 1H), 2.66- 2.62(t, 1H, J = 17.2), 2.53-2.46(m, 3H), 2.33-2.28(m, 4H), 2.01-1.93(m, 1H), 1.51-1.48(m, 1H)
1H NMR (CDCl3) δ 7.67(m, 1H), 7.06-7.01(m, 1H), 6.97-6.94(m, 3H), 6.72-6.72(m, 1H), 6.54(s, 1H), 4.35- 4.05(m, 2H), 3.01- 3.00(m, 1H), 2.89- 2.88(m, 1H), 2.59- 2.57(m, 2H), 2.47- 2.41(m, 4H), 1.97- 1.96(m, 1H), 1.80(m, 1H)
1H NMR (CDCl3) δ 7.85(s, 1H), 7.41-7.40(t, 1H, J = 4.0), 7.23(s, 2H), 7.10-7.05(m, 2H), 6.93-6.90(m, 2H), 6.36(s, 1H), 4.09- 3.99(m, 2H), 2.63- 2.59(t, 1H, J = 17.2), 2.56-2.45(m, 3H), 2.32-2.28(m, 4H), 2.01-1.93(m, 1H), 1.50-1.46(m, 1H)
1H NMR (CDCl3) δ 8.03- 7.98(m, 1H), 7.41- 7.34(m, 2H), 7.26- 7.21(m, 2H), 7.17- 7.10(m, 2H), 6.49(s, 1H), 4.09-3.98(m, 2H), 2.63-2.59(t, 1H, J = 17.2), 2.51-2.46(m, 3H), 2.36-2.26(m, 4H), 2.00-1.91(m, 1H), 1.51-1.46(m, 1H)
1H NMR (CDCl3): δ 7.95- 7.81(m, 1H), 7.40- 7.19(m, 3H), 7.18- 7.06(m, 1H), 6.89- 6.65(m, 4H), 4.34- 4.18(m, 1H), 4.09- 3.94(m, 1H), 2.89- 2.51(m, 5H), 2.42(s, 3H), 2.07-1.95(m, 1H), 1.78-1.60(m, 1H)
1H NMR (CDCl3) δ 7.96- 7.94(m, 1H), 7.63(s, 1H), 7.55-7.52(m, 2H), 7.42-7.37(m, 2H), 7.21-7.17(m, 2H), 6.40(s, 1H), 4.09- 3.99(m, 2H), 2.64- 2.60(t, 1H, J = 17.2), 2.55-2.47(m, 3H), 2.36-2.31(m, 4H), 2.00-1.91(m, 1H), 1.51-1.46(m, 1H)
1H NMR (CDCl3) δ 7.97(m, 1H), 7.07-7.03(m, 1H), 6.94-6.89(m, 2H), 6.74-6.73(m, 1H), 6.45(s, 1H), 4.08- 3.99(m, 2H), 3.83- 3.79(m, 3H), 2.63- 2.59(t, 1H, J = 17.2), 2.54-2.47(m, 3H), 2.36-2.27(m, 4H), 2.00-1.91(m, 1H), 1.49-1.45(m, 1H)
1H NMR (CDCl3) δ 7.82(m, 1H), 7.65(s, 1H), 7.54-7.51(m, 2H), 7.13-7.08(m, 1H), 6.96-6.93(m, 2H), 6.34(s, 1H), 4.07- 3.97(m, 2H), 2.60- 2.56(t, 1H, J = 17.2), 2.53-2.43(m, 3H), 2.34-2.35(m, 4H), 1.98-1.90(m, 1H), 1.49-1.44(m, 1H)
1H NMR (CDCl3) δ 7.93(m, 1H), 7.31-7.29(m, 2H), 7.23-7.13(m, 2H), 7.06-7.01(m, 1H), 6.91-6.89(m, 1H), 6.42(s, 1H), 4.07- 3.96(m, 2H), 2.61- 2.56(t, 1H, J = 17.2), 2.53-2.43(m, 3H), 2.35-2.25(m, 4H), 2.00-1.89(m, 1H), 1.51-1.41(m, 1H)
1H NMR (CDCl3) δ 7.85(m, 1H), 7.14-7.13(m, 2H), 7.10-7.05(m, 1H), 6.98-6.96(m, 1H), 6.93-6.90(m, 1H), 6.43(s, 1H), 4.09- 3.99(m, 2H), 2.65- 2.60(t, 1H, J = 17.2), 2.55-2.47(m, 3H), 2.36-2.31(m, 4H), 2.02-1.95(m, 1H), 1.52-1.47(m, 1H)
1H NMR (CDCl3) δ 7.85(m, 1H), 7.40-7.38(m, 1H), 7.26-7.19(m, 2H), 7.08-7.03(m, 1H), 6.91-6.88(m, 1H), 6.34(s, 1H), 4.08- 3.97(m, 2H), 2.61- 2.57(t, 1H, J = 17.2), 2.55-2.47(m, 3H), 2.36-2.25(m, 4H), 2.00-1.90(m , 1H), 1.51-1.44(m, 1H)
1H NMR (CDCl3) δ 8.05(m, 1H), 7.44-7.40(m, 1H), 7.31-7.23(m, 2H), 7.21-7.17(m, 2H), 6.98-6.96(m, 1H), 4.13-4.07(m, 2H), 3.10-3.08(m, 1H), 2.49-2.45(m, 1H), 2.39(s, 3H), 2.29- 2.21(m, 1H), 1.95- 1.59(m, 4H)
1H NMR (CDCl3) δ 7.87- 7.85(m, 1H), 7.55- 7.17(m, 5H), 6.99(m, 1H), 6.55(s, 1H), 4.11-4.02(m, 2H), 3.06-3.02(m, 2H), 2.95-2.89(m, 1H), 2.85-2.81(m, 1H), 2.76-2.66(m, 1H), 2.62(s, 3H), 2.18- 2.09(m, 1H), 1.78- 1.69(m, 1H)
1H NMR (CDCl3) δ 7.86- 7.83(m, 1H), 7.53- 7.15(m, 4H), 6.99(m, 1H), 6.50(s, 1H), 4.10-4.02(m, 2H), 3.05-3.02(m, 2H), 2.97-2.90(m, 1H), 2.84-2.82(m, 1H), 2.77-2.67(m, 1H), 2.60(s, 3H), 2.18- 2.10(m, 1H), 1.79- 1.69(m, 1H)
1H NMR (CDCl3) δ 7.70(s, 1H), 7.44-7.42(d, 1H, J = 7.2), 7.26-7.20(m, 2H), 6.93-6.90(m, 1H), 6.75(m, 1H), 6.66(s, 1H), 4.15-4.00(m, 2H), 3.81(s, 3H), 3.42- 3.40(m, 1H), 2.81- 2.47(m, 2H), 2.34(s, 3H), 2.06-1.60(m, 4H)
1H NMR (CDCl3) δ 7.92(s, 1H), 7.43-7.27(m, 2H), 7.23-7.08(m, 3H), 7.03-6.95(m, 1H), 6.79(s, 1H), 4.33- 4.19(m, 2H), 3.28- 3.26(m, 1H), 2.75(m, 1H), 2.49-2.28(m, 4H), 1.98-1.59(m, 4H)
1H NMR (CDCl3) δ 7.90(s, 1H), 7.39-7.31(m, 2H), 7.22-7.05(m, 3H), 7.03-6.97(m, 1H), 6.72(s, 1H), 4.26- 4.11(m, 2H), 3.19- 3.14(m, 1H), 2.70- 2.64(m, 1H), 2.42- 2.30(m, 4H), 1.99- 1.58(m, 4H)
1H NMR (CDCl3): δ 7.97(s, 1H), 7.41- 7.33(m, 2H), 7.23- 7.21(m, 2H), 7.16- 7.10(m, 2H), 6.60(s, 1H), 4.10-4.01(m, 2H), 2.74-2.72(m, 1H), 2.65-2.45 (m, 5H), 2.37-2.34(m, 1H), 2.02-1.93(m, 1H), 1.57-1.49(m, 1H), 1.11(t, 3H, J = 7.2)
1H NMR (CDCl3): δ 7.95(s, 1H), 7.41- 7.34(m, 2H), 7.23- 7.21(m, 2H), 7.18- 7.12(m, 2H), 6.68(s, 1H), 4.14-4.04(m, 2H), 3.07-3.05(m, 1H), 2.93-2.90(m, 1H), 2.76-2.74(m, 1H), 2.67-2.64(m, 2H), 2.09-2.02(m, 1H), 1.70-1.65(m, 2H), 1.23(s, 6H)
1H NMR (CDCl3): δ 8.10- 7.92(bs, 1H), 7.57- 6.90(m, 7H), 4.71(s, 1H), 4.21-3.91(m, 3H), 2.73-2.16(m, 9H), 2.08- 1.84(m, 1H), 1.64- 1.39(m, 1H)
1H NMR (DMSO): δ 8.78(s, 1H), 8.20- 7.78(m, 3H), 7.78- 7.20(m, 7H), 3.99- 3.65(bs, 2H), 3.55- 3.26(bs, 1H), 2.60- 1.97(m, 7H), 1.88- 1.63(bs, 1H), 1.41- 1.14(bs, 1H)
1H NMR (CDCl3): δ 8.15- 8.00(bs, 1H), 7.43- 7.13(m, 3H), 7.12- 6.99(m, 1H), 6.82- 6.55(m, 4H), 4.18- 3.93(m, 2H), 3.87- 3.67(bs, 2H), 2.72- 2.41(m, 4H), 2.41- 2.19(m, 4H), 2.03- 1.83(m, 1H), 1.55- 1.40(m, 1H)
1H NMR (CDCl3): δ 8.03- 7.85(m, 1H), 7.74- 7.50(m, 4H), 7.47- 7.32(m, 1H), 7.26- 7.08(m, 2H), 6.71- 6.47(bs, 1H), 4.15- 3.90(m, 2H), 2.77- 2.48(m, 4H), 2.48- 2.25(bs, 4H), 2.09- 1.88(m, 1H), 1.63- 1.44(m, 1H)
1H NMR (CDCl3): δ 7.98(m, 1H), 7.43- 7.38(m, 3H), 7.31- 7.29(m, 1H), 7.26- 7.25(m, 1H), 7.23- 7.16(m, 2H), 6.48(s, 1H), 4.11-4.02(m, 2H), 2.94-2.80(m, 1H), 2.51-2.48(m, 1H), 2.44(s, 3H), 2.14- 2.01(m, 1H), 1.89- 1.55(m, 4H)
1H NMR (CDCl3): δ 7.91(m, 1H), 7.39- 7.36(m, 1H), 7.30- 7.26(m, 1H), 7.19- 7.17(m, 2H), 7.00- 6.97(m, 2H), 6.95- 6.92(m, 1H), 6.70(s, 1H), 4.12-4.06(m, 2H), 3.00-2.97(m, 1H), 2.75-2.70(m, 1H), 2.60(s, 3H), 2.18- 2.14(m, 1H), 1.90- 1.52(m, 4H)
1H NMR (CDCl3): δ 7.84(m, 1H), 7.41- 7.39(m, 1H), 7.23- 7.17(m, 4H), 7.09- 7.07(m, 1H), 4.18- 4.11(m, 2H), 3.27- 3.14(m, 1H), 2.89- 2.85(m, 1H), 2.74(s, 3H), 2.28-2.23(m, 1H), 1.93-1.48(m, 4H)
1H NMR (CDCl3): δ 7.94(m, 1H), 7.55- 7.42(m, 1H), 7.30- 7.22(m, 2H), 7.19- 7.15(m, 2H), 7.04- 7.00(m, 1H), 4.20- 4.08(m, 2H), 3.29- 3.17(m, 1H), 2.88- 2.85(m, 1H), 2.54(s, 3H), 2.33-2.28(m, 1H), 2.01-1.66(m, 4H)
1H NMR (CDCl3): δ 8.10- 8.03(m, 1H), 7.36- 7.02(m, 6H), 6.89- 6.85(m, 1H), 6.63(s, 1H), 4.22-4.02(m, 2H), 3.07-2.98(m, 1H), 2.51-2.41(m, 1H), 2.39(s, 3H), 2.49- 2.14(m, 1H), 1.96- 1.52(m, 4H)
1H NMR (CDCl3): δ 8.02- 8.00(m, 1H), 7.37- 7.25(m, 2H), 7.17- 7.08(m, 2H), 6.90- 6.78(m, 2H), 6.60(s, 1H), 4.23-4.03(m, 2H), 3.08-2.99(m, 1H), 2.51-2.36(m, 1H), 2.34(s, 3H), 2.29- 2.15(m, 1H), 1.99- 1.54(m, 4H)
1H NMR (CDCl3): δ 8.10- 8.08(d, 1H, J = 8.0), 7.39-7.10(m, 3H), 6.92-6.83(m, 1H), 6.66-6.61(m, 1H), 6.59(s, 1H), 6.52- 6.48(m, 1H), 4.28- 4.08(m, 2H), 3.14- 3.07(m, 1H), 2.59- 2.47(m, 1H), 2.38(s, 3H), 2.33-2.21(m, 1H), 2.02-1.58(m, 4H)
1H NMR (CDCl3): δ 8.11- 8.09(d, 1H, J = 8.0), 7.33-7.23(m, 2H), 7.18-7.14(m, 1H), 7.13-7.10(m, 1H), 6.91-6.87(m, 1H), 6.48(s, 1H), 4.26- 4.06(m, 2H), 3.12- 3.08(m, 1H), 2.53- 2.43(m, 1H), 2.37(s, 3H), 2.30-2.20(m, 1H), 1.98-1.63(m, 4H)
1H NMR (CDCl3): δ 8.02- 8.00(d, 1H, J = 7.6), 7.30-7.23(m, 2H), 7.21-7.09(m, 1H), 7.06-7.04(d, 2H, J = 8.8), 6.77-6.75(d, 2H, J = 8.8), 6.60(s, 1H), 4.28-4.08(m, 2H), 3.13-3.06(m, 1H), 2.57-2.45(m, 1H), 2.38(s, 3H), 2.33- 2.22(m, 1H), 1.99- 1.59(m, 4H)
1H NMR (CDCl3): δ 8.12- 7.99(m, 1H), 7.49- 7.28(m, 4H), 7.28- 7.02(m, 3H), 6.62- 6.49(bs, 1H), 4.26- 3.99(m, 2H), 3.12- 2.98(m, 1H), 2.53- 2.40(m, 1H), 2.36(s, 3H), 2.27-2.14(m, 1H), 1.98-1.81(m, 1H), 1.80- 1.55(m, 2H)
1H NMR (CDCl3): δ 8.10- 8.08(d, 1H, J = 8.0), 7.65-7.61(dd, 2H), J = 12.0), 7.55-7.42(m, 3H), 7.19-7.10(m, 1H), 6.57(s, 1H), 4.27- 4.07(m, 2H), 3.13- 3.05(m, 1H), 2.57- 2.47(m, 1H), 2.38(s, 3H), 2.33-2.21(m, 1H), 2.01-1.60(m, 4H)
1H NMR (CDCl3): δ 8.11- 8.09(d, 1H, J = 8.0), 7.39-7.08(m, 5H), 6.92-6.88(m, 1H), 6.32(s, 1H), 4.27- 4.12(m, 2H), 3.14- 3.08(m, 1H), 2.57- 2.53(m, 1H), 2.44(s, 3H), 2.31-2.21(m, 1H), 2.01-1.58(m, 4H)
1H NMR (CDCl3): δ 7.98- 7.96(d, 1H, J = 7.6), 7.30-7.26(m, 1H), 7.22-7.14(m, 2H), 7.11-7.05(m, 1H), 6.81-6.77(t, 2H, J = 16.8), 6.73-6.71(t, 1H, J = 4.4), 4.23- 4.08(m, 2H), 3.09- 3.05(m, 1H), 2.57- 2.50(m, 1H), 2.38(s, 3H), 2.36-2.22(m, 1H), 1.99-1.59(m, 4H)
1H NMR (CDCl3): δ 8.02- 8.00(d, 1H, J = 7.2), 7.68-7.65(m, 2H), 7.60-7.54(m, 2H), 7.41-7.37(m, 1H), 7.17-7.16(d, 2H, J = 4.4), 6.42(s, 1H), 4.22-4.04(m, 2H), 3.06-3.02(m, 1H), 2.35(s, 3H), 2.30- 2.24(q, 1H, J = 16.0), 2.02-1.55(m, 4H)
1H NMR (CDCl3): δ 8.09- 8.07(d, 1H, J = 7.6), 7.41-7.15(m, 4H), 7.08-7.00(m, 1H), 6.94(s, 2H), 6.82(s, 1H), 6.42(s, 1H), 6.69-6.66(t, 1H, J = 14.8), 6.61(s, 1H), 4.24-4.03(m, 2H), 3.11-3.02(m, 1H), 2.56-2.44(m, 1H), 2.40(s, 3H), 2.30- 2.17(m, 1H), 1.96- 1.58(m, 4H)
1H NMR (CDCl3): δ 7.75(s, 1H), 7.23- 6.97(m, 4H), 6.90- 6.85(m, 1H), 6.83(s, 1H), 4.31-4.15(m, 2H), 3.26(m, 1H), 2.81(m, 1H), 2.54(m, 1H), 2.47(s, 3H), 2.03- 1.64(m, 4H)
1H NMR (CDCl3): δ 7.88(s, 1H), 7.06- 7.01(m, 2H), 6.90- 6.78(m, 3H), 6.61(s, 1H), 4.18-3.94(m, 2H), 3.05-3.00(m, 1H), 2.45-2.36(m, 1H), 2.33(s, 3H), 2.28- 2.12(m, 1H), 1.90- 1.52(m, 4H)
1H NMR (CDCl3): δ 7.82(s, 1H), 7.16- 6.98(m, 3H), 6.93- 6.90(m, 1H), 6.60(s, 1H), 4.29-4.07(m, 2H), 3.24(m, 1H), 2.51- 2.32(m, 2H), 2.15(s, 3H), 2.07-1.69(m, 4H)
1H NMR (CDCl3): δ 7.94(s, 1H), 7.23- 7.16(m, 2H), 7.07- 7.02(m, 2H), 6.92- 6.89(m, 2H), 6.56(s, 1H), 4.20-4.04(m, 2H), 3.07-3.03(m, 1H), 2.48-2.39(m, 1H), 2.36(s, 3H), 2.31- 2.19(m, 1H), 1.93- 1.55(m, 4H)
1H NMR (CDCl3): δ 7.89(s, 1H), 7.24(s, 1H), 7.22(s, 1H), 7.03-6.98(m, 2H), 6.88-6.85(m, 2H), 6.55(s, 1H), 4.16- 4.00(m, 2H), 3.04- 3.00(m, 1H), 2.47- 2.35(m, 1H), 2.32(s, 3H), 2.27-2.16(m, 1H), 1.90-1.51(m, 4H)
1H NMR (CDCl3): δ 7.89(s, 1H), 7.31- 7.28(m, 1H), 7.18(s, 1H), 7.16(s, 1H), 7.13-7.04(m, 1H), 6.83-6.81(m, 1H), 6.30(s, 1H), 4.16- 4.00(m, 2H), 3.04- 3.00(m, 1H), 2.47- 2.35(m, 1H), 2.32(s, 3H), 2.27-2.16(m, 1H), 1.90-1.51(m, 4H)
1H NMR (CDCl3) δ 7.88(s, 1H), 7.41-7.37(m, 1H), 7.21-7.16(m, 1H), 7.08-7.01(m, 2H), 6.91-6.88(m, 1H), 6.52(s, 1H), 4.24- 4.05(m, 2H), 3.12- 3.07(m, 1H), 2.53- 2.44(m, 1H), 2.38(s, 3H), 2.36-2.22(m, 1H), 1.94-1.56(m, 4H)
1H NMR (CDCl3): δ 7.86(s, 1H), 7.53- 7.49(m, 1H), 7.45- 7.40(m, 2H), 7.11- 7.05(m, 2H), 6.91- 6.88(m, 1H), 6.42(s, 1H), 4.18-4.02(m, 2H), 3.06-3.02(m, 1H), 2.45-2.39(m, 1H), 2.34(s, 3H), 2.28- 2.13(m, 1H), 1.91- 1.53(m, 4H)
1H NMR (CDCl3): δ 7.85(s, 1H), 7.26- 7.19(m, 1H), 7.02- 6.96(m, 1H), 6.93- 6.90(m, 1H), 6.78- 6.74(m, 3H), 6.71(s, 1H), 4.21-4.18(m, 2H), 3.15-3.11(m, 1H), 2.62-2.56(m, 1H), 2.41(s, 3H), 2.34- 2.27(m, 1H), 1.98- 1.62(m, 4H)
1H NMR (CDCl3): δ 7.81(s, 1H), 7.25- 7.22(m, 1H), 7.11(s, 1H), 7.07-6.91(m, 4H), 6.67(s, 1H), 4.30- 4.09(m, 2H), 3.21- 3.13(m, 1H), 2.71- 2.58(m, 1H), 2.39(s, 3H), 2.03-1.56(m, 4H)
1H NMR (CDCl3): δ 8.02(m, 1H), 7.39- 7.38(dd, 1H, J = 4.4), 7.27-7.25(m, 1H), 7.21-7.18(m, 1H), 7.01-6.98(dd, 1H, J = 7.2), 6.50(s, 1H), 4.23-4.10(m, 2H), 3.10-3.07(m, 1H), 2.50-2.46(m, 1H), 2.39(s, 3H), 2.28- 2.23(m, 1H), 1.95- 1.60(m, 4H)
1H NMR (CDCl3): δ 8.00(m, 1H), 7.41- 7.39(m, 1H), 7.28- 7.23(m, 1H), 7.20- 7.19(m, 1H), 7.00- 6.96(dd, 1H, J = 7.2), 6.61(s, 1H), 4.22- 4.10(m, 2H), 3.11- 3.09(m, 1H), 2.50- 2.46(m, 1H), 2.38(s, 3H), 2.29-2.21(m, 1H), 1.95-1.59(m, 4)
1H NMR (CDCl3): δ 7.96(m, 1H), 7.41- 7.38(m, 1H), 7.30- 7.26(m, 2H), 7.19- 7.15(m, 2H), 7.01- 6.93(m, 2H), 6.38(s, 1H), 4.21-4.14(m, 2H), 3.35(m, 1H), 3.00- 2.64(m, 1H), 2.48(s, 3H), 2.26-2.03(m, 3H), 1.94-1.67(m, 4H)
1H NMR (CDCl3): δ 7.90(m, 1H), 7.44- 7.41(m, 1H), 7.26- 7.19(m, 4H), 7.09- 7.06(m, 1H), 6.46(s, 1H), 4.25(m, 2H), 3.80(m, 1H), 2.98(m, 1H), 2.73(s, 3H), 2.29-2.15(m, 3H), 2.02-1.57(m, 4H)
1H NMR (CDCl3): δ 7.94(m, 1H), 7.60- 7.37(m, 2H), 7.26- 7.21(m, 2H), 7.06- 6.99(m, 2H), 6.40(s, 1H), 4.22-4.20(m, 2H), 3.83(m, 1H), 2.99(m, 1H), 2.73(s, 3H), 2.31-2.15(m, 3H), 2.02-1.59(m, 4H)
1H NMR (CDCl3): δ 7.92(m, 1H), 7.42- 7.39(m, 1H), 7.37- 7.34(m, 1H), 7.29- 7.28(m, 1H), 7.22- 7.17(m, 2H), 7.14- 7.11(m, 1H), 6.45(s, 1H), 4.22-4.14(m, 2H), 3.80(m, 1H), 3.47- 3.45(m, 1H), 2.53(s, 3H), 2.16-2.11(m, 3H), 1.98-1.72(m, 4H)
1H NMR (CDCl3): δ 8.00(m, 1H), 7.41- 7.37(m, 3H), 7.33- 7.27(m, 1H), 7.25- 7.20(m, 1H), 7.19- 7.14(m, 2H), 6.61(s, 1H), 4.08-4.01(m, 2H), 2.88-2.79(m, 1H), 2.49-2.45(m, 1H), 2.40(s, 3H), 2.28- 2.14(m, 1H), 1.94- 1.61(m, 4H)
1H NMR (CDCl3): δ 7.98(m, 1H), 7.41- 7.37(m, 1H), 7.29- 7.23(m, 1H), 7.17- 7.14(m, 2H), 6.99- 6.89(m, 2H), 6.44(s, 1H), 4.23-4.05(m, 2H), 3.10-3.07(m, 1H), 2.49(m, 1H), 2.38(s, 3H), 2.28-2.22(m, 3H), 1.93-1.60(m, 4H)
1H NMR (CDCl3): δ 8.00(m, 1H), 7.38- 7.34(m, 1H), 7.29- 7.23(m, 2H), 7.20- 7.14(m, 2H), 7.02- 6.89(m, 1H), 6.51(s, 1H), 4.20-4.05(m, 2H), 3.08-3.05(m, 1H), 2.58-2.44(m, 1H), 2.39(s, 3H), 2.30- 2.24(m, 3H), 1.99- 1.64(m, 4H)
1H NMR (CDCl3): δ 7.97(m, 1H), 7.43- 7.39(m, 1H), 7.23- 7.08(m, 4H), 7.04- 6.98(m, 1H), 6.52(s, 1H), 4.27-4.15(m, 2H), 3.17-3.07(m, 1H), 2.62(m, 1H), 2.44(s, 3H), 2.34-2.30(m, 3H), 1.95-1.58(m, 4H)
1H NMR (CDCl3): δ 8.07- 8.05(m, 1H), 7.33- 7.30(m, 1H), 7.18- 7.16(m, 1H), 7.10- 7.06(m, 1H), 7.03(s, 1H), 6.95(s, 2H), 6.69(s, 1H), 4.09- 3.99(m, 2H), 2.69- 2.65(t, 1H, J = 17.2), 2.59-2.40(m, 3H), 2.35-2.27(m, 4H), 2.01-1.95(m, 1H), 1.54-1.48(m, 1H)
1H NMR (CDCl3): δ 8.07- 7.89(bs, 1H), 7.40- 7.29(m, 1H), 7.29- 7.19(m, 1H), 7.19- 7.07(m, 2H), 7.07- 6.97(m, 1H), 6.97- 6.86(m, 1H), 6.61- 6.45(bs, 1H), 4.13- 3.92(m, 2H), 2.68- 2.43(m, 4H), 2.39(s, 3H), 2.36-2.20(m, 4H), 2.04-1.88(m, 1H), 1.53-1.39(m, 1H)
1H NMR (CDCl3): δ 7.98(m, 1H), 7.89- 7.04(m, 6H), 6.55(s, 1H), 4.08-3.97(m, 2H), 2.63-2.59(t, 1H, J = 17.2), 2.53-2.40(m, 2H), 2.35-2.31(m, 3H), 2.31(s, 1H), 2.27- 2.23(m, 1H), 1.99- 1.92(m, 1H), 1.51- 1.44(m, 1H)
1H NMR (CDCl3): δ 7.95(m, 1H), 7.47- 7.41(m, 2H), 7.12- 7.04(m, 4H), 6.93- 6.91(m, 1H), 6.48(s, 1H), 4.08-3.97(m, 2H), 2.63-2.59(t, 1H, J = 17.2), 2.52-2.49(m, 3H), 2.34-2.27(m, 4H), 2.00-1.93(m, 1H), 1.50-1.46(m, 1H)
1H NMR (CDCl3): δ 7.92(m, 1H), 7.42- 7.33(m, 2H), 7.23- 7.21(m, 2H), 7.07- 7.03(m, 1H), 6.93- 6.90(m, 1H), 6.27(s, 1H), 4.08-3.97(m, 2H), 2.65-2.60(t, 1H, J = 17.2), 2.53-2.45(m, 3H), 2.35-2.29(m, 4H), 2.01-1.93(m, 1H), 1.53-1.46(m, 1H)
1H NMR (CDCl3): δ 7.87(s, 1H), 7.40- 7.38(m, 1H), 7.25- 7.21(m, 2H), 7.08- 7.03(m, 1H), 6.90(dd, 1H, J = 8.8, 2.8), 6.50(s, 1H), 4.09- 3.98(m, 2H), 2.72(t, 1H, J = 8.8), 2.64- 2.44(m, 5H), 2.36- 2.33(m, 1H), 2.02- 1.92(m, 1H), 1.55- 1.47(m, 1H), 1.09(t, 3H, J = 7.2)
1H NMR (CDCl3): δ 8.14- 8.01(m, 1H), 7.51- 7.29(m, 6H), 7.23- 7.05(m, 2H), 6.75- 6.60(bs, 1H), 4.24- 4.00(m, 2H), 3.10- 2.98(m, 1H), 2.53- 2.29(m, 4H), 2.28- 2.15(m, 1H), 1.97- 1.52(m, 4H)
1H NMR (CDCl3): δ 8.14- 8.01(m, 1H), 7.51- 7.29(m, 5H), 7.23- 7.05(m, 2H), 6.75- 6.60(bs, 1H), 4.24- 4.00(m, 2H), 3.10- 2.98(m, 1H), 2.53- 2.29(m, 4H), 2.28- 2.15(m, 1H), 1.97- 1.52(m, 4H)
1H NMR (CDCl3): δ 8.17- 8.01(m, 1H), 7.41- 7.27(m, 2H), 7.22- 7.02(m, 5H), 6.76- 6.63(bs, 1H), 4.22- 4.00(m, 2H), 3.09- 2.98(m, 1H), 2.52- 2.30(m, 7H), 2.29- 2.12(m, 1H), 1.97- 1.80(m, 1H), 1.80- 1.50(m, 3H)
1H NMR (CDCl3): δ 7.97(s, 1H), 7.45- 7.37(m, 3H), 7.32- 7.25(m, 3H), 7.05- 7.00(m, 1H), 6.94- 6.91(m, 1H), 6.59(s, 1H), 4.19-4.04(m, 2H), 3.06-3.04(m, 1H), 2.35(s, 3H), 2.28- 2.18(m, 2H), 1.90- 1.76(m, 2H), 1.61- 1.57(m, 2H)
1H NMR (CDCl3): δ 7.82(s, 1H), 7.30- 7.11(m, 3H), 7.01- 6.85(m, 3H), 4.30- 4.07(m, 2H), 3.24- 3.21(m, 1H), 2.43(s, 3H), 2.35(s, 3H), 1.96-1.84(m, 2H), 1.79-1.72(m, 2H), 1.67-1.51(m, 2H)
1H NMR (CDCl3): δ 7.97(s, 1H), 7.43- 7.39(m, 1H), 7.11- 7.03(m, 4H), 6.91(d, 1H, J = 8.4), 6.48(s, 1H), 4.19-4.04(m, 2H), 3.05-3.02(m, 1H), 2.35(s, 3H), 2.26- 2.17(m, 2H), 1.88- 1.83(m, 2H), 1.71- 1.69(m, 2H)
1H NMR (CDCl3): δ 7.97(s, 1H), 7.31- 7.26(m, 1H), 7.22- 7.12(m, 2H), 7.06- 7.00(m, 2H), 6.91- 6.88(m, 1H), 6.43(s, 1H), 4.21-4.03(m, 2H), 3.06-3.02(m, 1H), 2.35(s, 3H), 2.28- 2.15(m, 2H), 1.95- 1.83(m, 2H), 1.70- 1.67(m, 2H)
1H NMR (CDCl3): δ 7.96(s, 1H), 7.47- 7.43(m, 2H), 7.40- 7.36(m, 1H), 7.33- 7.25(m, 2H), 7.18- 7.10(m, 1H), 6.81- 6.75(m, 2H), 4.18- 4.05(m, 2H), 3.03- 3.01(m, 1H), 2.35(s, 3H), 2.22-2.17(m, 2H), 1.93-1.86(m, 2H), 1.61-1.57(m, 2H)
1H NMR (CDCl3): δ 7.96(s, 1H), 7.45- 7.39(m, 2H), 7.25- 7.23(m, 1H), 7.16- 7.07(m, 2H), 7.03- 7.01(m, 1H), 6.83- 6.78(m, 1H), 6.65(s, 1H), 4.19-4.06(m, 2H), 3.05-3.02(m, 1H), 2.36(s, 3H), 2.26- 2.18(m, 2H), 1.93- 1.84(m, 2H), 1.59- 1.50(m, 2H)
1H NMR (CDCl3): δ 7.92(s, 1H), 7.45- 7.41(m, 2H), 7.33- 7.25(m, 2H), 7.16- 7.13(m, 1H), 7.02(s, 1H), 6.59(s, 1H), 4.21-4.05(m, 2H), 3.09-3.07(m, 1H), 2.38(s, 3H), 2.32(s, 3H), 2.27-2.23(m, 2H), 1.90-1.87(m, 2H), 1.78-1.72(m, 2H)
1H NMR (CDCl3): δ 7.88(s, 1H), 7.42- 7.36(m, 1H), 7.21- 7.20(m, 1H), 7.17- 7.15(m, 1H), 7.10- 7.03(m, 2H), 7.00(m, 1H), 6.55(s, 1H), 4.22-4.06(m, 2H), 3.10-3.06(m, 1H), 2.38(s, 3H), 2.31(s, 3H), 2.27-2.21(m, 2H), 1.94-1.85(m, 2H), 1.78-1.69(m, 2H)
1H NMR (CDCl3): δ 7.95(s, 1H), 7.15(m, 2H), 7.04-6.98(m, 2H), 6.93-6.90(m, 2H),, 6.72(s, 1H), 4.31- 4.17(m, 2H), 3.14(m, 1H), 2.82(m, 1H), 2.61-2.03(m, 10H), 1.99-1.62(m, 4H)
1H NMR (CDCl3): δ 7.83(s, 1H), 7.72- 7.70(m, 2H), 7.67- 7.52(m, 2H), 7.03- 6.91(m, 2H), 6.76(s, 1H), 4.35-4.22(m, 2H), 3.20(m, 1H), 2.96(m, 1H), 2.68-2.65(m, 1H), 2.48(s, 3H), 1.99- 1.63(m, 4H), 1.51- 1.29(m, 9H)
1H NMR (CDCl3): δ 7.84(s, 1H), 7.24- 7.15(m, 1H), 7.12- 6.89(m, 4H), 6.64(s, 1H), 4.26-4.10(m, 2H), 3.16-3.15(m, 1H), 2.62(m, 1H), 2.42(s, 3H), 2.38-2.32(m, 1H), 1.99-1.60(m, 4H)
1H NMR (CDCl3): δ 8.05(m, 1H), 7.57- 7.48(m, 1H), 7.22- 7.14(m, 2H), 7.12- 7.00(m, 2H), 6.61(s, 1H), 4.23-4.16(m, 2H), 3.22-3.10(m, 1H), 2.58-2.47(m, 1H), 2.38(s, 3H), 2.35- 2.30(m, 3H), 1.98- 1.60(m, 4H)
1H NMR (CDCl3): δ 7.39- 7.31(m, 3H), 7.20- 7.00(m, 2H), 6.98- 6.88(d, 1H, J = 2.8), 4.34-4.23(m, 2H), 3.45(m, 1H), 3.16(m, 1H), 2.57-2.54(m, 4H), 2.11-1.70(m, 4H).
1H NMR (CDCl3): δ 7.99(s, 1H), 7.23- 7.19(m, 1H), 7.03- 6.98(m, 1H), 6.93- 6.90(m, 1H), 6.74(m, 1H), 6.70-6.66(m, 1H), 6.63(s, 1H), 4.24- 4.07(m, 2H), 3.46(s, 1H), 3.14(m, 1H), 2.59(m, 1H), 2.42(s, 3H), 2.33-2.29(m, 1H), 1.98-1.63(m, 4H)
1H NMR (CDCl3): δ 7.84(s, 1H), 7.69- 7.66(m, 1H), 7.53- 7.50(m, 1H), 7.37- 7.33(m, 1H), 7.15- 7.10(m, 1H), 6.98- 6.95(m, 1H), 6.61(s, 1H), 4.29-4.15(m, 2H), 3.27(s, 1H), 2.78- 2.70(m, 1H), 2.48- 2.35(m, 4H), 1.98- 1.70(m, 4H)
1H NMR (CDCl3): δ 7.96(s, 1H), 7.79(s, 1H), 7.61(s, 1H), 7.50-7.47(d, 1H, J = 11.6), 7.11-7.06(m, 1H), 6.94-6.91(m, 1H), 6.58(s, 1H), 4.27- 4.11(m, 2H), 3.22- 3.17(m, 1H), 2.67- 2.66(m, 1H), 2.42- 2.32(m, 4H), 2.02- 1.60(m, 4H)
1H NMR (CDCl3): δ 7.82(s, 1H), 7.02- 6.64(m, 5H), 4.17- 4.09(m, 2H), 3.10- 3.06(m, 1H), 2.53(m, 1H), 2.37(s, 3H), 2.34-2.21(m, 1H), 1.96-1.62(m, 4H)
1H NMR (CDCl3): δ 7.94(s, 1H), 7.66- 7.44(m, 4H), 6.91- 6.89(d, 1H, J = 8.4), 6.62(s, 1H), 4.23- 4.08(m, 2H), 3.86- 3.85(m, 3H), 3.11(m, 1H), 2.53(m, 1H), 2.34(s, 3H), 2.29- 2.28(m, 1H), 1.93- 1.63(m, 4H)
1H NMR (CDCl3): δ 8.11(m, 1H), 7.44- 7.36(m, 1H), 7.20- 7.17(m, 2H), 7.10- 6.99(m, 2H), 6.54(s, 1H), 4.27-4.21(m, 2H), 3.31-3.15(m, 1H), 2.44-2.40(m, 1H), 2.39(s, 1H), 2.30- 2.25(m, 3H), 2.01- 1.55(m, 4H)
1H NMR (CDCl3): δ 7.58- 7.53(m, 1H), 7.48- 7.44(m, 2H), 7.29- 7.15(m, 2H), 6.95- 6.92(m, 1H), 6.84- 6.79(m, 1H), 4.27- 4.23(m, 2H), 4.14- 4.07(q, 2H, J = 6.8), 3.28(m, 1H), 2.89(m, 1H), 2.50(m, 4H), 1.98-1.59(m, 4H), 1.46-1.40(t, 3H, J = 14.0)
1H NMR (CDCl3): δ 7.65- 7.61(m, 1H), 7.54- 7.52(m, 1H), 7.47- 7.43(m, 2H), 7.33(m, 1H), 6.68-6.65(m, 1H), 4.29-4.15(m, 2H), 3.87(s, 6H), 3.28- 3.25(m, 1H), 2.78- 2.70(m, 1H), 2.48- 2.35(m, 4H), 1.98- 1.63(m, 4H)
1H NMR (CDCl3): δ 7.93(s, 1H), 7.03- 6.91(m, 4H), 6.46- 6.42(m, 1H), 6.38(s, 1H), 4.22-4.08(m, 2H), 3.77(s, 6H), 3.15(m, 1H), 2.61(m, 1H), 2.41(s, 3H), 2.36- 2.24(m, 1H), 1.93- 1.58(m, 4H)
1H NMR (CDCl3): δ 7.81(s, 1H), 7.43- 7.28(m, 4H), 7.20- 7.19(d, 1H, J = 4.4), 6.87-6.86(dd, 1H, J = 9.2), 6.76-6.75(d, 1H, J = 2.8), 6.61(s, 1H), 4.20-4.06(m, 2H), 3.77(s, 3H), 3.13- 3.10(m, 1H), 2.58- 2.43(m, 1H), 2.38(s, 3H), 2.32-2.25(m, 1H), 1.92-1.56(m, 4H)
1H NMR (CDCl3): δ 7.74(s, 1H), 7.39- 7.33(m, 1H), 7.10- 7.01(m, 2H), 6.88- 6.85(m, 1H), 6.73- 6.72(m, 1H), 6.59(s, 1H), 4.17-4.03(m, 2H), 3.76(s, 3H), 3.76(m, 1H), 2.49(m, 1H), 2.36(s, 3H), 2.28- 2.21(m, 1H), 1.99- 1.56(m, 4H)
1H NMR (CDCl3): δ 7.79(s, 1H), 7.37- 7.33(m, 2H), 7.26- 7.20(m, 2H), 6.91- 6.88(m, 1H), 6.73- 6.72(m, 1H), 6.38(s, 1H), 4.22-4.05(m, 2H), 3.79(s, 3H), 3.11- 3.07(m, 1H), 2.50- 2.38(m, 1H), 2.33(s, 3H), 2.29-2.22(m, 1H), 1.94-1.57(m, 4H)
1H NMR (CDCl3): δ 7.69(s, 1H), 7.48- 7.43(m, 2H), 7.21- 7.17(m, 1H), 6.90- 6.87(m, 1H), 6.71- 6.70(m, 1H), 6.51(s, 1H), 4.21-4.05(m, 2H), 3.78(s, 3H), 3.13(m, 1H), 2.52-2.45(m, 1H), 2.32(s, 3H), 2.30- 2.22(m, 1H), 1.97- 1.59(m, 4H)
1H NMR (CDCl3): δ 7.79(s, 1H), 7.64(m, 1H), 7.35-7.34(m, 1H), 7.23-7.22(m, 1H), 7.07-7.02(m, 1H), 6.90-6.87(m, 1H), 6.63(s, 1H), 4.26- 4.05(m, 2H), 3.20- 3.15(m, 1H), 2.66(m, 1H), 2.42-2.32(m, 4H), 1.99-1.61(m, 4H)
4′-Fluoro-[1,1′-biphenyl]-2-carboxylic acid (747 mg, 3.46 mmol) (Synthesis Example 1) was dissolved in toluene (20 mL), and then biphenylphosphoryl azide (958 μL, 4.15 mmol) and triethylamine (486 μL, 3.46 mmol) were added thereto. The same was stirred at room temperature for 30 minutes, and then stirred again under reflux for 1 hour. The reactant was cooled to room temperature. 2-(2-Hydroxyethyl)-1-methylpyrrolidine (558 μL, 4.15 mmol) was added thereto and stirred under reflux for 12 hours. The reactant was cooled to room temperature. The solvent was removed by concentrating under reduced pressure, and then the same was extracted with water and ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (280 mg, 24%).
The starting materials in Table 7 were used instead of 4′-fluoro-[1,1′-biphenyl]-2-carboxylic acid (747 mg, 3.46 mmol) (Synthesis Example 1) to prepare compounds of Examples 2-16 in the same manner as Example 1.
3′-Chloro-5-fluoro-[1,1′-biphenyl]-2-carboxylic acid (300 mg, 1.20 mmol) (Synthesis Example 16) was dissolved in toluene (20 mL), and then biphenylphosphoryl azide (310 μL, 1.44 mmol) and triethylamine (202 μL, 1.44 mmol) was added thereto. The same was stirred at room temperature for 30 minutes, and then stirred again under reflux for 1 hour. The reactant was cooled to room temperature. 2-(2-Hydroxyethyl)-1-methylpyrrolidine (194 μL, 1.44 mmol) were added thereto and then stirred under reflux for 12 hours. The reactant was cooled to room temperature. The solvent was removed by concentrating under reduced pressure, and then the same was extracted with water and ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (93 mg, 21%).
The starting materials in Table 7 were used instead of 3′-chloro-5-fluoro-[1,1′-biphenyl]-2-carboxylic acid (300 mg, 1.20 mmol) (Synthesis Example 16) to prepare compounds of Examples 18-27 in the same manner as Example 17.
2-(1-Methylpyrrolidin-2-yl)ethyl (2-iodophenyl)carbamate (600 mg, 1.6 mmol) (Synthesis Example A) was dissolved in a mixed solution of toluene (20 mL) and ethanol (4 mL). 4-Cyanophenyl boronic acid (259 mg, 1.76 mmol), potassium carbonate (442 mg, 3.2 mmol) and tetrakis triphenylphosphine palladium (370 mg, 0.32 mmol) were added thereto. The reactant was stirred at 110° C. for 12 hours and cooled to room temperature. The same was filtered through celite and the solvent was removed by concentrating under reduced pressure. The same was extracted with water and ethyl acetate, and then the organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (193 mg, 35%).
2-(1-Methylpyrrolidin-2-yl)ethyl (2-iodophenyl)carbamate of Synthesis Example A as a starting material and reaction materials in Table 9 were used to prepare compounds of Examples 29-32 in the same manner as Example 28.
2-(1-Methylpyrrolidin-2-yl)ethyl (2-iodophenyl)carbamate (1.36 g, 3.63 mmol) (Synthesis Example A) was dissolved in a mixed solution of acetonitrile (15 mL) and water (15 mL). 3-Aminophenyl boronic acid (995 mg, 7.26 mmol), sodium carbonate (772 mg, 7.26 mmol) and dichlorobis triphenylphosphine palladium (127 mg, 0.18 mmol) were added thereto. The reactant was stirred at 110° C. in a microwave oven for 10 minutes and cooled to room temperature. The same was filtered through celite and the solvent was removed by concentrating under reduced pressure. The same was extracted with water and ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (192 mg, 16%).
2-(1-Methylpyrrolidin-2-yl)ethyl (2-iodophenyl)carbamate of Synthesis Example A as a starting material and reacting materials in Table 10 were used to prepare compounds of Examples 34-41 in the same manner as Example 33.
2-(1-Methylpyrrolidin-2-yl)ethyl(2-bromo-4-fluoro-phenyl)carbamate (400 mg, 1.16 mmol)(Synthesis Example B) was dissolved in toluene (20 mL). 3,4-Fluorophenyl diboronic acid (280 mg, 1.74 mmol), potassium carbonate (321 mg, 2.32 mmol) and tetrakis triphenylphosphine palladium (140 mg, 0.12 mmol) were added thereto. The reactant was stirred at 120° C. for 12 hours and cooled to room temperature. The same was filtered through celite and the solvent was removed by concentrating under reduced pressure. The same was extracted with water and ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (15 mg, 3%).
2-(1-Methylpyrrolidin-2-yl)ethyl(2-bromo-4-fluoro-phenyl)carbamate of Synthesis Example B as a starting material and reacting materials in Table 11 were used to prepare compounds of Examples 43-46 in the same manner as Example 42.
2-(1-Methylpyrrolidin-2-yl)ethyl(2-bromo-4-(trifluoro-methyl)phenyl)carbamate of Synthesis Example C as a starting material instead of 2-(1-methylpyrrolidin-2-yl)ethyl (2-bromo-4-fluorophenyl)carbamate of Synthesis Example B and reacting materials in Table 12 were used to prepare compounds of Examples 47-51 in the same manner as Example 42.
2-(1-Methylpyrrolidin-2-yl)ethyl(2-bromo-4-fluoro-phenyl)carbamate (300 mg, 0.87 mmol)(Synthesis Example B) was dissolved in a mixed solution of acetonitrile (10 mL) and water (10 mL). (3-Chloro-5-fluorophenyl)boronic acid (303 mg, 1.74 mmol), sodium carbonate (184 mg, 1.74 mmol) and dichlorobis triphenylphosphine palladium (31 mg, 0.04 mmol) were added thereto. The reactant was stirred at 110° C. in a microwave oven for 10 minutes and cooled to room temperature. The same was filtered through celite and the solvent was removed by concentrating under reduced pressure. The same was extracted with water and ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (51 mg, 15%).
2-(1-Methylpyrrolidin-2-yl)ethyl(2-bromo-4-fluoro-phenyl)carbamate of Synthesis Example B as a starting material and reacting materials in Table 13 were used to prepare compounds of Examples 53-59 in the same manner as Example 52.
2-(1-Methylpyrrolidin-2-yl)ethyl(2-bromo-4-methoxy-phenyl)carbamate of Synthesis Example D instead of 2-(1-methylpyrrolidin-2-yl)ethyl (2-bromo-4-fluorophenyl)carbamate of Synthesis Example B as a starting material and reacting materials in Table 14 were used to prepare compounds of Examples 60-65 in the same manner as Example 52.
2-(1-Methylpyrrolidin-2-yl)ethyl(2-bromo-4-chloro-phenyl)carbamate of Synthesis Example E instead of 2-(1-methylpyrrolidin-2-yl)ethyl (2-bromo-4-fluorophenyl)carbamate of Synthesis Example B as a starting material and reacting materials in Table 15 were used to prepare compounds of Examples 66-73 in the same manner as Example 52.
(R)-(1-methylpyrrolidin-3-yl)methyl(2-bromophenyl)-carbamate (220 mg, 0.70 mmol) (Synthesis Example F) and 3-fluoro-4-formylphenylboronic acid (237 mg, 1.41 mmol) were used as starting materials to prepare titled compound (124 mg, 50%) in the same manner as Example 52.
2-(1-Methylpyrrolidin-2-yl)ethyl(3′,5′-difluoro-5-methoxy-[1,1′-biphenyl]-2-yl)carbamate (130 mg, 0.33 mmol) (Example 62) was dissolved in dichloromethane (10 mL). A boron trichloride solution (1.0M dichloromethane, 0.99 ml, 0.99 mmol) was added thereto and stirred at room temperature for 2 hours. After reaction was terminated, the reactant was extracted with water and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (68 mg, 55%).
2-(1-Methylpyrrolidin-2-yl)ethyl(3′,5′-dichloro-5-methoxy-[1,1′-biphenyl]-2-yl)carbamate (90 mg, 0.21 mmol) (Example 64) was used instead of Example 62 to prepare titled compound (10 mg, 12%) in the same manner as Example 75.
2-(1-Methylpyrrolidin-2-yl)ethyl (3′-chloro-4′-fluoro-5-methoxy-[1,1′-biphenyl]-2-yl)carbamate (140 mg, 0.34 mmol) (Example 65) was used instead of Example 62 to prepare titled compound (130 mg, 96%) in the same manner as Example 75.
[1,1′-Biphenyl]-2-carboxylic acid (2 g, 10.09 mmol) was dissolved in toluene (50 mL), and then biphenylphosphoryl azide (2.61 mL, 12.11 mmol) and triethylamine (1.42 mL, 10.09 mmol) were added thereto. The same was stirred at room temperature for 30 minutes and then stirred again under reflux for 1 hour. The reactant was cooled to room temperature. (R)-tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate (2.44 g, 12.11 mmol) was added thereto and stirred under reflux for 12 hours. The reactant was cooled to room temperature. The solvent was removed by concentrating under reduced pressure, and then the same was extracted with water and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (3 g, 75%).
1H NMR(CDCl3): δ 8.15-7.97 (bs, 1H), 7.55-7.26 (m, 6H), 7.26-7.05 (m, 2H), 6.67-6.52 (bs, 1H), 4.19-3.90 (m, 2H), 3.57-3.18 (m, 2H), 3.13-2.73 (bs, 1H), 2.57-2.38 (m, 1H), 2.00-1.83 (m, 1H), 1.70-1.53 (m, 2H) 1.43 (s, 9H)
(R)-tert-butyl 3-((([1,1′-biphenyl]-2-ylcarbamoyl)oxy)-methyl)pyrrolidine-1-carboxylate (3 g, 7.57 mmol) was dissolved in dichloromethane (80 mL). Trifluoroacetic acid (40 mL) was added thereto and stirred at room temperature for 2 hours. The solvent was removed by concentrating the reactant under reduced pressure and the same was extracted with 2N-sodium hydroxide solution and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (1.73 g, 77%).
Starting materials and reacting materials in Table 16 were used to prepare compounds of Examples 79-88 in the same manner as Example 78.
(R)-pyrrolidin-3-ylmethyl [1,1′-biphenyl]-2-ylcarbamate (727 mg, 2.45 mmol) (Example 78) was dissolved in water (50 mL). Acetic acid (1 mL), formaldehyde solution (3 mL) and zinc powder (300 mg) were sequentially added thereto and stirred at room temperature for 12 hours. The reactant was filtered, neutralized with 2N-sodium hydroxide and extracted with water and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (209 mg, 28%).
Starting materials in Table 17 were used instead of (R)-pyrrolidin-3-ylmethyl [1,1′-biphenyl]-2-ylcarbamate to prepare compounds of Examples 90-99 in the same manner as Example 89
3′-Methyl-[1,1′-biphenyl]-2-carboxylic acid (Synthesis Example 14) and (R)-tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate were used as starting materials to prepare the titled compound in the same manner as Example 78.
1H NMR(CDCl3): δ 8.13-7.97 (bs, 1H), 7.41-7.28 (m, 2H), 7.26-7.02 (m, 5H), 6.77-6.62 (bs, 1H), 4.13-3.92 (m, 2H), 3.09-2.82 (m, 3H), 2.72-2.49 (m, 2H), 2.47-2.30 (m, 4H), 1.97-1.81 (m, 1H), 1.50-1.36 (m, 1H)
(R)-pyrrolidin-3-ylmethyl(3′-methyl-[1,1′-biphenyl]-2-yl)carbamate (600 mg, 1.93 mmol) prepared in Step 1 was used to prepare the titled compound (30 mg, 5%) in the same manner as Example 89.
3′-Methyl-[1,1′-biphenyl]-2-carboxylic acid (Synthesis Example 14) and (S)-tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate were used as starting materials to prepare the titled compound in the same manner as Example 78.
1H NMR(CDCl3): δ 8.15-7.99 (bs, 1H), 7.45-7.29 (m, 2H), 7.27-7.06 (m, 5H), 6.74-6.59 (bs, 1H), 4.15-3.92 (m, 2H), 3.07-2.79 (m, 4H), 2.69-2.57 (m, 1H), 2.39 (s, 3H), 2.07-1.92 (bs, 1H) 1.92-1.79 (m, 1H), 1.48-1.33 (m, 1H)
(S)-pyrrolidin-3-ylmethyl (3′-methyl-[1,1′-biphenyl]-2-yl)carbamate (900 mg, 2.90 mmol) prepared in Step 1 was used to prepare the titled compound (208 mg, 22%) in the same manner as Example 89.
(R)-pyrrolidin-3-ylmethyl [1,1′-biphenyl]-2-ylcarbamate (1 g, 3.37 mmol) (Example 78) was dissolved in dimethylformamide (20 mL). Potassium carbamate (652 mg, 4.72 mmol), potassium iodide (112 mg, 0.67 mmol), triethylamine (1.42 mL, 10.11 mmol) and iodoethane (323 μL, 4.04 mmol) were sequentially added thereto and stirred at 120° C. for 12 hours. The reactant was cooled to room temperature and extracted with water and ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (142 mg, 13%).
Starting materials in Table 18 were used instead of (R)-pyrrolidin-3-ylmethyl [1,1′-biphenyl]-2-ylcarbamate to prepare compounds of Examples 103-105 in the same manner as Example 102.
(S)-pyrrolidin-2-ylmethyl [1,1′-biphenyl]-2-ylcarbamate (1 g, 3.37 mmol) and 2-iodoethane (323 μL, 4.04 mmol) were used as starting materials to prepare titled compound (385 mg, 35%) in the same manner as Example 102.
(S)-pyrrolidin-2-ylmethyl [1,1′-biphenyl]-2-ylcarbamate (940 mg, 3.17 mmol) and 1-iodo-2-methylpropane (438 μL, 3.08 mmol) were used as starting materials to prepare titled compound (47 mg, 4%) in the same manner as Example 102.
3′,5-Difluoro-[1,1′-biphenyl]-2-carboxylic acid (800 mg, 3.42 mmol) (Synthesis Example 17) and (S)-tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate (825 mg, 4.10 mmol) were used as starting materials to prepare titled compound (50 mg, 5%) in the same manner as Example 78 and Example 89.
[1,1′-Biphenyl]-2-carboxylic acid (821 mg, 4.14 mmol) and (R)-tert-butyl-2-(hydroxymethyl)pyrrolidine-1-carboxylate (1 g, 4.97 mmol) were used as starting materials to prepare titled compound (730 mg, 60%) in the same manner as Example 78.
1H NMR (CDCl3): δ 8.09-8.08 (m, 1H), 7.49-7.47 (m, 1H), 7.29-7.26 (m, 1H), 7.17 (m, 1H), 6.92-6.89 (m, 1H), 4.15-4.04 (m, 2H), 3.12-3.08 (m, 1H), 2.99-2.94 (m, 2H), 2.74-2.72 (m, 1H), 2.51-2.44 (m, 1H), 1.98-1.89 (m, 1H), 1.51-1.44 (m, 1H)
(R)-pyrrolidin-2-ylmethyl [1,1′-biphenyl]-2-ylcarbamate (730 mg, 2.46 mmol) was used as a starting material to prepare titled compound (183 mg, 24%) in the same manner as Example 89.
3′-Methyl-[1,1′-biphenyl]-2-carboxylic acid (700 mg, 3.3 mmol) (Synthesis Example 14) and (R)-tert-butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate (797 mg, 3.96 mmol) were used as starting materials to prepare titled compound (258 mg, 24%) in the same manner as Example 78 and Example 89.
(1 g, 4.34 mmol) (Synthesis Example 21) and (R)-tert-butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate (1.05 g, 5.21 mmol) were used as starting materials to prepare titled compound (52 mg, 4%) in the same manner as Example 78 and Example 89.
[1,1′-Biphenyl]-2-carboxylic acid (2.5 g, 12.61 mmol) and (S)-tert-butyl-2-(hydroxymethyl)pyrrolidine-1-carboxylate (3.05 g, 15.14 mmol) were used as starting materials to prepare titled compound (3.06 g, 82%) in the same manner as Example 78.
1H NMR (CDCl3) δ 7.88 (m, 1H), 7.48-7.42 (m, 1H), 7.15-7.05 (m, 4H), 7.04-6.92 (m, 1H), 6.40 (s, 1H), 4.78-4.76 (m, 1H), 3.23-3.21 (m, 1H), 2.87-2.73 (m, 4H), 2.06-2.05 (m, 3H), 2.04-1.67 (m, 1H), 1.66-1.54 (m, 1H), 1.53-1.35 (m, 1H)
(S)-pyrrolidin-2-ylmethyl [1,1′-biphenyl]-2-ylcarbamate (1 g, 3.37 mmol) and 2-iodopropyl (404 μL, 4.04 mmol) were used as starting materials to prepare titled compound (78 mg, 7%) in the same manner as Example 102.
(R)-(1-methylpyrrolidin-3-yl)methyl(2-bromophenyl)-carbamate (230 mg, 0.73 mmol) (Synthesis Example F) was dissolved in a mixed solution of ethanol (5 mL) and water (5 mL). 3-Fluorophenylboronic acid (123 mg, 0.88 mmol), potassium carbonate (203 mg, 1.47 mmol), di(acetato)dicyclo-hexylphenylphosphine palladium(II) and Polymer-bound FibreCat™ (30 mg) were added thereto. The reactant was stirred at 110° C. for 12 hours and then cooled to room temperature. The same was filtered through celite and the solvent was removed by concentrating under reduced pressure. The same was extracted with water and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (60 mg, 25%).
Reacting materials in Table 19 was used instead of 3-fluorophenylboronic acid to prepare compounds of Examples 114-115.
(S)-(1-methylpyrrolidin-3-yl)methyl(2-bromophenyl)-carbamate (200 mg, 0.64 mmol) (Synthesis Example G) was dissolved in toluene (10 mL). 3-Fluorophenylboronic acid (179 mg, 1.28 mmol), potassium carbonate (177 mg, 1.28 mmol) and tetrakis triphenylphosphine palladium (74 mg, 0.064 mmol) were added thereto. The reactant was stirred at 110° C. for 12 hours and cooled to room temperature. The same was filtered through celite and the solvent was removed by concentrating under reduced pressure. The same was extracted with water and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (102 mg, 49%).
Starting materials and reacting materials in Table 20 were used to prepare compounds of Examples 117-129 in the same manner as Example 116.
(R)-(1-methylpyrrolidin-3-yl)methyl(2-bromophenyl)-carbamate (225 mg, 0.72 mmol) (Synthesis Example F) was dissolved in a mixed solution of ethanol (5 mL) and water (5 mL). 3,4-Dichlorophenylboronic acid (274 mg, 1.44 mmol), potassium carbonate (199 mg, 1.44 mmol) and tetrakis triphenylphosphine palladium (83 mg, 0.072 mmol) were added thereto. The reactant was stirred at 110° C. for 6 hours and cooled to room temperature. The same was filtered through celite and the solvent was removed by concentrating under reduced pressure. The same was extracted with water and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (151 mg, 560).
Starting materials and reacting materials in Table 21 were used to prepare compounds of Examples 131-135 in the same manner as Example 130.
(R)-(1-methylpyrrolidin-3-yl)methyl(2-bromophenyl)-carbamate (250 mg, 0.80 mmol) (Synthesis Example F) was dissolved in a mixed solution of acetonitrile (6 mL) and water (6 mL). (3-Chloro-4-fluorophenyl)boronic acid (279 mg, 1.60 mmol), sodium carbonate (170 mg, 1.60 mmol) and dichlorobistriphenylphosphine palladium (28 mg, 0.04 mmol) were added thereto. The reactant was stirred in a microwave oven at 110° C. for 30 minutes and cooled to room temperature. The same was filtered through celite and the solvent was removed by concentrating under reduced pressure. The same was extracted with water and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (23 mg, 70%).
Starting materials and reacting materials in Table 22 were used to prepare compounds of Examples 137-149 in the same manner as Example 136.
(R)-tert-butyl-3-((((2-bromophenyl)carbamoyl)oxy)-methyl)pyrrolidine-1-carboxylate (4 g, 10.02 mmol) (Synthesis Example F, Step 1) and (3-chloro-4-fluoro)phenylboronic acid (3.5 g, 20.04 mmol) were used as starting materials to prepare titled compound (3.4 g, 76%) in the same manner as Example 42.
1H NMR (CDCl3): δ 8.01 (s, 1H), 7.41-7.35 (m, 2H), 7.31-7.22 (m, 2H), 7.20-7.13 (m, 2H), 6.34 (s, 1H), 4.15-4.07 (m, 2H), 3.48-3.29 (m, 3H), 3.15-2.99 (s, 1H), 2.51-2.48 (m, 1H), 1.98-1.94 (m, 1H), 1.44-1.38 (m, 10H)
(R)-tert-butyl-3-((((3′-chloro-4′-fluoro-[1,1′-biphenyl]-2-yl)carbamoyl)oxy)methyl)pyrrolidine-1-carboxylate (3.4 g, 7.57 mmol) prepared in Step 1 was used as a starting material to prepare titled compound (2.3 g, 87%) in the same manner as Example 78.
1H NMR (CDCl3): δ 7.98 (s, 1H), 7.41-7.34 (m, 2H), 7.23-7.17 (m, 2H), 7.16-7.11 (m, 2H), 6.55 (s, 1H), 4.10-4.01 (m, 2H), 3.99-2.86 (m, 3H), 2.70-2.66 (s, 1H), 2.45-2.39 (m, 1H), 1.95-1.86 (m, 1H), 1.47-1.41 (m, 1H)
(R)-pyrrolidin-3-ylmethyl-(3′-chloro-4′-fluoro-[1,1′-biphenyl]-2-yl)carbamate (345 mg, 0.99 mmol) prepared in Step 2 was dissolved in tetrahydrofuran (20 mL). Triethylamine (150 μL, 1.09 mmol) and bromoethane (118 μL, 1.58 mmol) were sequentially added thereto and stirred at room temperature for 3 days. The reactant was concentrated under reduced pressure and extracted with water and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (74 mg, 20%).
(R)-pyrrolidin-3-ylmethyl-(3′-chloro-4′-fluoro-[1,1′-biphenyl]-2-yl)carbamate (347 mg, 1.00 mmol) (Example 150, Step 2) was dissolved in tetrahydrofuran (20 mL). Triethylamine (150 μL, 1.10 mmol) and 2-bromopropane (100 μL, 1.10 mmol) were sequentially added thereto and stirred at room temperature for 3 days. The reactant was concentrated under reduced pressure and extracted with water and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (17 mg, 4%).
(R)-(1-methylpyrrolidin-3-yl)methyl-(2-bromophenyl)-carbamate (395 mg, 1.26 mmol) (Synthesis Example F) was dissolved in a mixed solution of toluene (15 mL) and ethanol (2 mL). 3-(Hydroxymethyl)phenylboronic acid (211 mg, 1.39 mmol), potassium carbonate (348 mg, 2.52 mmol) and tetrakis triphenylphosphine palladium (146 mg, 0.13 mmol) were added thereto. The reactant was stirred at 110° C. for 12 hours and cooled to room temperature. The same was filtered through celite and the solvent was removed by concentrating under reduced pressure. The same was extracted with water and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (126 mg, 29%).
Starting materials and reacting materials in Table 23 were used to prepare compounds of Examples 153-190 in the same manner as Example 152.
(R)-(1-methylpyrrolidin-3-yl)methyl(2-bromophenyl)-carbamate (220 mg, 0.70 mmol) (Synthesis Example F) was dissolved in a mixed solution of ethanol (5 mL) and water (5 mL). 3,5-Dimethylboronic acid (211 mg, 1.41 mmol), potassium carbonate (194 mg, 1.41 mmol), di(acetato)dicyclohexylphenyl-phosphine palladium(II) and Polymer-bound FibreCat™ (28 mg) were added thereto. The reactant was stirred in a microwave oven at 110° C. for 30 minutes and cooled to room temperature. The same was filtering through celite and the solvent was removed by concentrating under reduced pressure. The same was extracted with water and dichloromethane. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (134 mg, 56%).
Starting materials and reacting materials in Table 24 were used to prepare compounds of Examples 192-195 in the same manner as Example 191.
2-Bromo-4-fluorobenzoic acid (3 g, 13.70 mmol) and (R)-tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate (3.31 g, 16.44 mmol) were used as starting materials to prepare titled compound (4.5 g, 79%) in the same manner as Synthesis Example F.
1H NMR (CDCl3): δ 8.00 (s, 1H), 7.28-7.24 (m, 1H), 7.05-7.00 (m, 1H), 4.21-4.10 (m, 2H), 3.06-3.03 (m, 1H), 2.90-2.87 (m, 1H), 2.84-2.71 (m, 5H), 2.17-2.12 (m, 1H), 1.76-1.71 (m, 1H), 1.24 (t, 3H, J=7.2)
(R)-(1-ethylpyrrolidin-3-yl)methyl(2-bromo-4-fluoro-phenyl)carbamate (165 mg, 0.48 mmol) and (3-chloro-4-fluoro-phenyl)boronic acid (167 mg, 0.96 mmol) were used as starting materials to prepare titled compound (143 mg, 76%) in the same manner as Example 136.
[1,1′-Biphenyl]-2-carboxylic acid (1 g, 5.05 mmol) was dissolved in toluene (20 mL). Biphenylphosphoryl azide (1.4 mL, 6.05 mmol) and triethylamine (0.71 mL, 5.05 mmol) were added thereto. The same was stirred at room temperature for minutes, and then stirred again under reflux at room temperature for 1 hour. The reactant was cooled to room temperature and (S)-(1-methylpyrrolidin-2-yl)methanol (0.72 mL, 6.05 mmol) was added thereto, and then stirred under reflux for 12 hours. The reactant was cooled to room temperature. The solvent was removed by concentrating under reduced pressure. The same was extracted with water and ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (458 mg, 29%).
Starting materials and reacting materials in Table 25 were used to prepare compounds of Examples 198-207 in the same manner as Example 197.
(S)-(1-methylpyrrolidin-2-yl)methyl(2-bromo-4-fluoro-phenyl)carbamate (200 mg, 0.60 mmol)(Synthesis Example N) was dissolved in a mixed solution of acetonitrile (3 mL) and water (3 mL). 3,5-Dimethylphenylboronic acid (181 mg, 1.20 mmol), sodium carbonate (95 mg, 0.90 mmol) and dichlorobistriphenylphosphine palladium (2 mg, 0.003 mmol) were added thereto. The reactant was stirred in a microwave oven at 150° C. for 10 minutes and cooled to room temperature. The same was filtered through celite and the solvent was removed by concentrating under reduced pressure. The same was extracted with water and ethyl acetate. The organic layer was dried with anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified with column chromatography to prepare the titled compound (98 mg, 46%).
Starting materials and reacting materials in Table 26 were used to prepare compounds of Examples 209-226 in the same manner as Example 208.
Cell membrane proteins (Perkin Elmer) wherein human muscarinic M3 receptor was overexpressed, [3H]-methyl scopolamine and test compounds in various concentration were cultured in 0.2 ml of Tris-HCl buffer at 25° C. for 120 minutes. The same was filtered under suction through glass fiber filter (Whatman GF/B), and then the filter was washed 5 times with 1 ml of Tris-HCl buffer. The radioactivity of [3H]-methyl scopolamine adsorbed on the filter was measured by a liquid scintillation counter. Non-specific binding was evaluated under existence of 5 μM of atropine. Affinity of the compound of the present invention to muscarinic M3 receptor was calculated as the dissociation constant (Ki), which can be calculated from concentration (IC50) of test compounds inhibiting 50% of binding of [3H]-methyl scopolamine (i.e. labeled ligand) according to Cheng and Prusoff [Cheng and Prusoff, Biochem. Pharmacol., 22, 3099, 1973]. In following Table, compounds having stronger binding affinity to human muscarinic M3 receptor have lower dissociation constant (Ki).
The antagonism assay for various compounds of the present invention was conducted on antagonism to human M3 receptor in Cos-7 cells that was transfected with plasmid coding human muscarinic M3 receptor. Test compounds in various concentrations were pre-treated to the cells for 3 minutes, and then the changes of intracellular calcium were measured after treating the same with carbachol (i.e. muscarinic receptor agonist). The FLIPR® Calcium 5 assay (Molecular Devices) and Flex3 device (Molecular Devices) were used to measure concentration of calcium. Amounts of calcium before and after carbachol treatment were set as 0% and 100% respectively. Inhibition rates (%) by the compounds for increase in intracellular calcium by carbachol were calculated. The antagonistic potency of the test compounds on human muscarinic M3 receptor was calculated as the functional binding constant (Kb), which can be calculated from concentration (IC50) of compound inhibiting 50% of activity of carbachol according to Cheng and Prusoff equation. The compounds used in the experiment were identified as antagonists for human muscarinic M3 receptor, and lower Kb value means superior antagonistic potency.
Female Sprague-Dawley rat was halothane-anesthetized, and a polyethylene catheter was inserted through urethra lay down straight and fixed. Urine in bladder was excreted through the catheter by gently massaging abdomen of the rat, and then removed. A three-way stopcock was connected to the catheter and a pressure transducer was connected to one side of the three-way stopcock to measure pressure, and a syringe was installed at the other side to inject 37° C. of saline solution. The saline solution was slowly injected until regular bladder contractions occurred repeatedly. When regular bladder contractions occurred stably, test compounds were administered intravenously through the tail vein. Inhibitory effect of the test compounds was evaluated by measuring degree of amplitude reduction of bladder contractions. The compounds of the present invention significantly reduced amplitude of bladder contractions when the compounds were administered at least 0.3 mg/kg or more.
In order to confirm acute toxicity of the compounds of the present invention, following experiment was conducted. A low-dose group, a medi-dose group and a high-dose group, wherein the compounds of Examples were administered 100 mg/kg, 300 mg/kg and 1000 mg/kg respectively, were prepared. Methyl cellulose solution (0.5%) was prepared and orally administered to 3 rats of each group (i.e. both sexes of 6-week old Sprague-Dawley (SD) rats; male rats in 142-143 g; female rats in 126.3-127.3 g) in a volume of 10 mL/kg. Mortality, clinical signs and weight and the like were measured for 4 days, and discovered approximate lethal dose (ALD) therefrom were explained in Table 30 below. As shown in Table 30, approximate lethal dose of the test compounds were 1000 mg/kg or more, therefore the compounds were determined as safe drugs.
The novel biphenyl derivatives, the isomers or pharmaceutically acceptable salts thereof according to the present invention acts as a muscarinic M3 receptor antagonist, and thus can be useful for the prevention or treatment of a disease selected from the group consisting of chronic obstructive pulmonary disease, asthma, irritable bowel syndrome, urinary incontinence, rhinitis, spasmodic colitis, chronic cystitis, Alzheimer's disease, senile dementia, glaucoma, schizophrenia, gastroesophageal reflux disease, cardiac arrhythmia, and hyper salivation syndrome.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2013-0090175 | Jul 2013 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2014/006483 | 7/17/2014 | WO | 00 |
